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9REVIEW OF THE LITERATURE
1. PLATELET MEMBRANE GLYCOPROTEINS AND FCγ RECEPTORS
1.1. Introduction to platelet physiology
Platelets prevent and arrest haemorrhage from blood vessel wall defects. The complex haemostatic
system comprises the interactions of the vessel wall and of various plasma proteins as well as the
platelets. Platelet membrane glycoproteins (GP) function as physiological receptors and mediate
interactions between the vascular subendothelium and the platelets (adhesion) and platelet-platelet
interaction (aggregation) as platelets respond to thrombogenic stimuli.
Platelets are produced by bone marrow megakaryocytes. A single mature megakaryocyte is suggested
to ultimately produce several thousand platelets. Normally, the megakaryocytes give rise to nearly 2
x 1011 platelets daily (Majerus, 1994). Megakaryopoiesis and thrombopoiesis are regulated by
cytokines, such as thrombopoietin (Kaushansky, 1998). Patients with depressed platelet production
are reported to have higher thrombopoietin levels than patients in whom peripheral platelet destruction
is increased (Emmons et al, 1996; Porcelijn et al, 1998). Moreover, the thrombopoietin levels of
patients with increased peripheral platelet destruction seems to differ only slightly from those of
healthy controls (Ichikawa et al, 1996; Kosugi et al, 1996a). In different conditions, the bone marrow
may increase platelet production approximately five- to ten-fold, thereby maintaining the normal
platelet count (Majerus, 1994). Normally, two thirds of the total platelet mass is circulating at
concentrations of 150 to 400 x 109/l, the rest remains in the splenic circulation.
Platelets are anucleate cells with diameters of 2 to 4 µm, and a cell volume of approximately 10 fl
(Majerus, 1994). Platelets change, upon activation, from a disc shape to a compact sphere with long
extensions facilitating adhesion (Fig 1). The change in shape and retraction of the clot are mediated
by the cytoplasmic actin and myosin. In addition to other cell organelles, such as peroxisomes,
mitochondria and lysosomes, platelets contain dense granules and α-granules which secrete various
substances and the proteins needed in platelet aggregation and coagulation reactions.
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Fig 1. Electron micrograph of resting and activated platelets. Published with the permission of The Lancet:
George JN. Platelets. Lancet 2000;355:1531-9.
Platelets have been demonstrated to vary in volume and density (Corash et al, 1977; Ault, 1993;
Jackson & Carter, 1993). In general, platelet morphology may be studied from a peripheral blood
smear, and the size distribution of the circulating platelets may be estimated with automated cell
counters or flow cytometry. Some studies have shown that, in normal conditions, the platelet volume
and density are unrelated to platelet age (Boneu et al, 1977; Mezzano et al, 1981). After acute
bleeding, however, newly synthesised platelets are larger and have a higher density and increased
ribonucleic acid (RNA) content (Ingram & Coopersmith, 1969; Ault & Knowles, 1995). In cases of
intensive peripheral platelet destruction, the megakaryocytic cytoplasm and nuclear deoxyribonucleic
acid (DNA) increase in quantity and the megakaryocytes seem to produce a platelet population with
a greater mean and greater dispersion of volume (Boneu et al, 1977; Martin & Trowbridge, 1983).
Moreover, the mean platelet volume in bone marrow blood has been shown to be higher than that
observed in peripheral blood, suggesting that the newly formed cell population consists of larger
platelets (Aliberti et al, 1996). The heterogeneity of platelet size can also be explained partly by
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platelet microparticles, which are platelet-derived vesicles too small to be detected in routine platelet
counting. The levels of the microparticles have been shown to be higher in patients with increased
peripheral platelet destruction (Nomura et al, 1991; Jy et al, 1992). The significance of platelet
microparticles still remains unknown, and the heterogeneity of platelet size and the characteristics of
newly synthesised platelets are still of wide interest.
Investigation of platelet survival and determination of platelet sequestration are used for measurements
of platelet kinetics. Platelet lifespan measurements may be performed by monitoring labelled and
transfused platelets. Different radioisotopes, especially Indium-111, have been used as labels
(International Committee for Standardisation in Hematology Panel on Diagnostic Applications of
Radionuclides, 1988). However, isolation and labelling of platelets with radioisotopes form obstacles.
Non-isotopic methods have also been applied for measurements of platelet lifespan, such as inhibition
of monoamine oxidase or cyclo-oxygenase enzymes as well as biotinylation of platelets (Ault &
Knowles, 1995; Dale, 1997). In general, however, platelet survival studies are considered to be
complicated and to suffer from the requirement of several procedures, and therefore, they are rarely
used clinically.
Normally, platelets with a mean lifespan of 7 to 10 days are destroyed in the spleen. The liver has also
been suggested to be an important site of platelet destruction, especially in patients with increased
peripheral platelet destruction (Aster & Jandl, 1964; Panzer et al, 1986; Najean et al, 1997). Accessory
spleens may also maintain increased platelet destruction. In conditions with increased peripheral
platelet destruction, the survival of cells ranges from a few days to a matter of minutes. For studies
of the pathophysiological mechanisms of thrombocytopenia more practical measurements of platelet
kinetics have proved necessary. Quantification of newly formed platelets would be useful and more
easily adapted for clinical purposes and thus have advantages over platelet survival studies. In the
circulation platelets with a high nucleic acid content, reticulated platelets (RP), have been thought to
represent young platelets, and thus measurement of RP may give an estimate of megakaryocyte
stimulation and platelet production (Ingram & Coopersmith, 1969; Kienast & Schmitz, 1990; Ault et
al, 1992; Richards & Baglin, 1995).
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1.2. Platelet membrane glycoproteins (GP)
Characteristics of the major platelet GPs are presented in Table 1. Target antigens of platelet
autoantibodies have most frequently been studied in the GP IIbIIIa and GP IbIX complexes (van
Leeuwen et al, 1982; Beardsley et al, 1984; Woods et al, 1984a & b; McMillan et al, 1987; Tomiyama
et al, 1987 & 1989; Berchtold et al, 1989a; Kokawa et al, 1993). GP IIbIIIa and GP IbIX have been
recognised to be the most immunogenic of the platelet glycoproteins, carrying some recognised
autoepitopes, as well as the known alloantigens, clinically important polymorphisms (Kunicki &
Newman, 1992; Ouwehand & Navarrete, 2000; Table 1). The Human Platelet Antigen (HPA) system
is used as the nomenclature for the platelet-specific alloantigens (http://www.nibsc.ac.uk/Haem).
1.2.1. GP IIbIIIa
GP IIb and GP IIIa are among the major GPs in the platelet plasma membrane (Fig 2). The GP IIbIIIa
complex is a member of the superfamily of integrins, consisting of α and β heterodimers (αIIbβ3; Table
1). The GP IIbIIIa complex is required for normal platelet aggregation. This complex is capable of
binding not only to fibrinogen, but also to other adhesive proteins, such as fibronectin, vitronectin and
von Willebrand factor. The GP IIbIIIa complex appears very early at the promegakaryoblastic stage,
and it is considered the earliest marker of the megakaryocytic lineage. Upon activation,
conformational changes and clustering of GP IIbIIIa have been demonstrated.
The calcium-dependent heterodimeric GP IIbIIIa complex is the most abundant glycoprotein on the
platelet surface; 45 000 to 50 000 copies of GP IIbIIIa are exposed on each resting platelet (Table 1).
The complex has been recognised to be the most immunogenic of the platelet glycoproteins, carrying
most of the known alloantigens (Table 1). GP IIIa is the carrier of most of the HPAs described so far
(Table 1). The genes for GP IIb and IIIa have been localised to chromosome 17. The gene for GP IIb
spans a 22 kilobase length of DNA, whereas the gene for IIIa is larger, containing 14 exons and spans
over 60 kilobases (Prandini et al, 1988; Lanza et al, 1990). GP IIb is composed of two disulphide-
linked polypeptide chains: IIbα and transmembrane IIbβ, and the GP IIIa is a single-chain
transmembrane polypeptide with multiple interchain disulphide bonds. Total absence or defective cell
surface expression of platelet GP IIbIIIa is characteristic of Glanzmann´s thrombasthenia with
impaired platelet aggregation and adhesion.
13
Table 1. Platelet membrane glycoproteins (GP) and their physical properties.
GP Molecular Gene Ligand for Autoepitopic Platelet Molecules on Other cells
(subunits) CD weight† HPA family Complex the complex regions** function resting platelet expressing GP
IIb (α) 41 125 3, 9w, Va* integrin IIbIIIa fibrinogen, vWf, 1) 65 kDa carboxyterm. aggregation, 45 000 megakaryocytes
IIb (β) 23 integrin fibronectin,
vitronectin
1) 2E7, aa 231-238 adhesion at
high shear
45 000 megakaryocytes
IIIa 61 95 1, 4, 6w,
7w, 8w,
10w, 11w,
Oe*
integrin 1) 33 kDa cysteine-rich
2) cytoplasmic
carboxyterminal
3) aa 734-739
4) IIbIIIa complex
rates 45 000 megakaryocytes,
endothelium,
fibroblasts,
smooth muscle
Ib (α) 42b 141 2, Pe* leucine-rich IbIXV vWf, thrombin 1) close to membrane
2) extracellular
epitopes
adhesion 25 000 megakaryocytes,
endothelium
Ib (β) 42c 22 12w leucine-rich 25 000
IX 42a 20 leucine-rich 25 000
V 42d 80 Plt* leucine-rich (?) 11 000
Ia 49b 155 5, 13w integrin IaIIa collagen adhesion,
aggregation
†† activated T lymphocytes,
endothelium, other cell types
IIa 29 138 integrin 10 000 endothelium
IV=IIIb 36 97 Vis* (-) thrombospondin,
collagen
adhesion 15 000 monocytes, endothelium,
erythroblasts
VI 67 Ig-domain collagen activation ?
FcγRIIA 32 40 Ig-domain Fc fragment of
IgG
immune
contact
600-8000 neutrophils, eosinophils, basophils,
monocytes, macrophages
GMP-140 62 140 selectin oligosaccharides
of leucocytes
cellular
interactions
(-) endothelium
* Private platelet alloantigens in the complex. † Molecular weight of unreduced protein in kDa. ** Autoepitopes recognised by circulating antibodies. †† IaIIa complex: 800-
3500/platelet.
aa: amino acids; CD: cluster of differentiation; GMP: granule membrane protein; HPA: human platelet antigen, Ig: immunoglobulin; vWf: von Willebrand factor.
Ref: Szatkowski et al, 1986; Tsubakio et al, 1987; Tomiyama et al, 1989; Kunicki et al, 1990, 1991a & b; Fujisawa et al, 1991 & 1992; Kekomäki et al, 1991; Kunicki &
Newman, 1992; He et al, 1995; Bowditch et al, 1996.
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Fig 2. Platelet glycoprotein complex GP IIbIIIa. Human platelet antigens (HPA) are indicated. (Modified from
http://www.nibsc.ac.uk/Haem, published with the permission.)
1.2.2. GP IbIXV
GP IbIX is involved in the adhesion of platelets to the exposed vascular subendothelium. In the
circulation, with its high shear stress rates, this complex functions as a receptor for von Willebrand
factor. The binding of von Willebrand factor to platelet GP IbIX causes platelet activation, which
promotes the recruitment of additional platelets. Probably, GP Ib also plays a role in thrombin activation,
since it appears to contain a binding site for thrombin. The GP IbIX complex also serves as a site of
attachment for the cytoskeleton to the plasma membrane.
The leucine-rich proteins GP Ib and GP IX form a non-covalent, functional complex, and are integral
membrane proteins spanning the lipid bilayer (Fig 3). The GP Ib has two disulphide-linked subunits, Ibα
and β. The major and extramembranous portion of GP Ibα is called glycocalicin. The glycocalicin
concentration in plasma has been suggested to reflect platelet turnover and platelet membrane injury in
vivo (Beer et al, 1994). Yet the method for measuring glycocalicin has not been standardised, since
methodological difficulties have limited its clinical applications. GP IX and GP V are composed of single
GPIIb / IIIa
β3 αIIb
CD61 / CD41
GPIIIa GPIIbβ
Fibrinogen
binding site
RGD
binding site
GPIIbα
COOHCOOH
HPA - 7
HPA - 6
Oea
HPA - 9
HPA - 3
HPA - 4
HPA - 10
HPA - 1
Groa
HPA - 8
Ca++
Ca++
Ca++
Ca++
s
s
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polypeptide chains, which form a non-covalent complex in the platelet membrane (Modderman et al,
1992; Fig 3). The genes for GP Ibα and GP Ibβ are located in chromosomes 17 and 22, respectively,
whereas the genes for GP IX and GP V are located in chromosome 3. The genes for the GP IbIXV
complex are relatively small, only a few kilobases, which is partly due to their few introns (Wenger et
al, 1988; Yagi et al, 1995). In systematic screening, nine polymorphic sites have been found in the GP
V gene, four of them leading to an amino acid change in the protein (Koskela, 1999).
GP Ibα, in addition to its HPA-2 polymorphism, has also been demonstrated to carry a length
polymorphism and several silent polymorphism sites (Koskela, 1999). Defects in the GP IbIXV complex
lead to impaired platelet function and diminished platelet survival in the autosomally recessively
inherited macrothrombocytopenia known as Bernard-Soulier syndrome (López et al, 1998; Koskela,
1999).
Fig 3. Platelet glycoprotein complex GP IbIXV. Human platelet antigens (HPA) are indicated. (Modified from
http://www.nibsc.ac.uk/Haem, published with the permission.)
Actin-binding protein
GPIb / IX / V
CD42
GPIX GPIbβ
GPIbα GPIbα
GPIX
GPIbβ
Iya
von Willebrand factor and thrombin
binding site
Molecular weight polymorphism (VNTR)HPA - 2
GPV
ss ss
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1.2.3. GP IaIIa
GP IaIIa is another member of the integrin superfamily of adhesion receptors (α2β1). At low shear rates,
the GP IaIIa complex functions as a receptor for collagen, and thus mediates a significant portion of the
adherence of platelets to the subendothelium.
GP IaIIa consists of two unique subunits: α2 (Ia) and β1 (IIa), which are composed of single polypeptide
chains containing numerous intra-chain disulphide bonds. GP Ia, which contains a transmembrane
domain and a short cytoplasmic segment, is widely expressed by a variety of cells (Table 1). GP IIa is
composed of a short cytoplasmic domain, which may vary in length because of alternative splicing. The
genes for GP Ia and GP IIa are located in chromosome 5 and they contain a single exon and seven exons,
respectively (Takada & Hemler, 1989). Two alloantigen systems have been reported on GP Ia, of which
HPA-5 has been demonstrated to be almost as important, clinically, as HPA-1.
1.3. Introduction to Fcγ receptors
Receptors for the Fc fragment of IgG (Fcγ receptors, FcγR) are considered to be a contact link in the
immune system. These proteins mediate contact between phagocytes and IgG-opsonised particles or cells.
Phagocytes, monocytes, macrophages, neutrophils, eosinophils and also platelets need FcγRs for binding,
ingestion and destruction of the opsonised particles. FcγRs on macrophages mediate the recognition and
binding of IgG-coated cells in the mononuclear-phagocyte system. Triggering of FcγRs induces activation
of phagocytes and leads to release of inflammatory mediators.
Three different subclasses of FcγRs have been identified: FcγR type I (FcγRI), FcγRII and FcγRIII
(McKenzie & Schreiber, 1994; Kimberley et al, 1995). The Fcγ receptor subclasses have been
demonstrated to be polymorphic and also to show different antibody binding affinities. Different cell
types express the different subclasses (Table 2). FcγRIA is the only FcγR capable of binding monomeric
IgG with high affinity. The three FcγRII genes, FcγRIIA, FcγRIIB and FcγRIIC, encode for proteins that
bind weakly to monomeric IgG but more strongly to the IgG in aggregates. FcγRI is the least polymorphic
of all the FcγRs, but both the FcγRIII genes, FcγRIIIA and FcγRIIIB, have been shown to be polymorphic
(Table 2). FcγRIIIA has a functionally important polymorphic site in amino acid 158 (V158F). FcγRIIIB
bears an important polymorphism of the neutrophil antigen (NA1/NA2) and a polymorphic site in amino
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acid 266 (SH266), which both have unknown structural and functional implications (Lehrnbecher et al,
1999). FcγRIIIB is the most abundant FcR on neutrophils. However, the significance of the variety of
FcγR subclasses related to genetic polymorphism, protein expression and ligand binding affinities
remains an interesting but poorly understood matter.
Table 2. Fcγ receptors (FcγR), receptors specific for Fc fragment of IgG
FcγRI FcγRII FcγRIII
CD 64 32 16
Gene transcripts* IA
IB1, IB2
IC
IIA
IIB1, IIB2, IIB3
IIC
IIIA
IIIB
Molecular weight 72 kDa 40 kDa 50 - 80 kDa
Affinity for ligand High Low IIIA: medium; IIIB: low
Expression at
the protein level
monocytes,
macrophages,
neutrophils†
IIA: neutrophils, basophils,
eosinophils, monocytes,
macrophages, platelets
IIB: B cells
IIIA: macrophages,
monocytes, NK cells
IIIB: neutrophils, eosinophils†
Polymorphism
(amino acid)
IIA: QW27
IIA: HR131
IIA: QK127
IIIA: LRH48
IIIA: VF158
IIIB: NA1/NA2 (36, 65, 82,106)
IIIB: null type
IIIB: SH266
* FcγR-encoding genes are all located on the q region of chromosome 1. † in contact with cytokines.
CD: cluster of differentiation; NA: neutrophil antigen; NK cells: natural killer cells.
References: McKenzie & Schreiber, 1994; Anderson et al, 1995; Kimberley et al, 1995; Koene et al, 1997; Norris et al,
1998; Lehrnbecher et al, 1999
The most widely expressed of all the FcγRs is FcγRII. The only FcγR expressed on platelets is FcγRIIA
(Rosenfeld et al, 1985). FcγRII is an integral membrane glycoprotein of 40 kDa with two extracellular
Ig-like domains, which is found on phagocytes, neutrophils, monocytes and macrophages and also at low
levels on B cells. In addition, there is a soluble form of the protein, which may alternatively be spliced,
lacking the transmembrane-encoding exon (Markovic et al, 1995). The FcγRIIA gene contains eight
exons. At present, three polymorphic FcγRIIA genes are known to result in changes in amino acid
positions 27 (Q27W), 127 (Q127K) and 131 (H131R).
18
2. THROMBOCYTOPENIA
2.1. Introduction to thrombocytopenia
The most common cause of abnormal bleeding is thrombocytopenia, defined as a subnormal platelet
concentration in the circulating blood. The aetiology of thrombocytopenia may involve three different
mechanisms: decreased platelet production, sequestration of cells or increased peripheral destruction of
platelets.
Decreased platelet production may be due to hypoplasia or suppression of megakaryocytes. Bone marrow
injury may be the consequence, for example, of neoplasias, myelosuppressive drugs, irradiation, aplastic
anaemia or viral infections. Ineffective or insufficient platelet production or defects in the regulation of
thrombopoiesis may also lead to decreased platelet production. Various disorders of the spleen may cause
abnormal sequestration of platelets. Increased peripheral platelet destruction may be due to numerous
conditions, and it commonly involves immunological processes. Autoimmune-mediated
thrombocytopenia is more frequently encountered than the alloimmune condition. Platelet utilisation in
intravascular thrombi or on damaged endothelial surfaces, such as are present in disseminated
intravascular coagulation, is considered to be a non-immunological process leading to thrombocytopenia.
In laboratory conditions, pseudothrombocytopenia due to platelet clumping may cause falsely low platelet
counts. Its prevalence is estimated to be 0.1% of routine blood counts. Pseudothrombocytopenia may be
diagnosed by examining the peripheral blood smear (Berkman et al, 1991; Silvestri et al, 1995). A low
platelet count in vitro, has been suggested to be due to the presence of agglutinating anticoagulant-
dependent antibodies. Agglutination has been reported in blood anticoagulated with EDTA, citrate,
oxalate or heparin. Such anticoagulant-induced thrombocytopenia should be recognised in order to avoid
unnecessary investigations and clinical consequences. Thus, all significantly low platelet counts should
be confirmed by a blood smear sample.
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2.2. Autoimmune thrombocytopenia
2.2.1. Autoimmune disease
Autoimmune diseases occur when self antigens are recognised as foreign entities, and they may be either
organ-specific or systemic disorders. It is agreed that genetic susceptibility, as well as potential
environmental agents, influences the aetiological course of an autoimmune disease. In general, the
induction of autoimmune disease probably involves T lymphocytes: autoimmune responses usually begin
with the activation of CD4+ T helper cells. The number of CD8+ T cells has then been demonstrated to
be increased; thus the CD4/CD8 T cell ratio is decreased. These T cells regulate autoantibody production
(Sinha et al, 1990). Thus, an imbalance in the regulation of the immune system causes the formation of
autoantibodies against self antigens by B lymphocytes. However, low levels of non-pathological ’natural’
autoantibodies may also be found in the normal state. Generally, susceptibility to autoimmunity is
thought to be polygenic. The polymorphic amino acid residues in hypervariable allelic regions of the
human leukocyte antigen (HLA) molecules have been shown to play an important role in determining
susceptibility or resistance to autoimmune diseases. HLA molecules usually present peptide fragments
of antigens to T cells. Different HLA molecules have different peptide-binding properties and are
selective for particular T cells. Since T cells have both a diverse and a central role in the immune system,
differences in HLA molecules may contribute to the development of an autoimmune disease.
Accordingly, many such diseases have been associated with certain major histocompatibility alleles
(Thorsby, 1997).
2.2.2. Pathophysiology of autoimmune thrombocytopenia
Platelet-specific autoantibodies may lead to enhanced Fc-mediated destruction of platelets by the
mononuclear phagocytosing system, most commonly in the spleen, but also in the liver. The
immunological nature of idiopathic thrombocytopenic purpura (ITP) was first confirmed by Harrington
and co-workers (1951), who demonstrated a circulating ’anti-platelet factor’ in human plasma as a
possible cause of increased peripheral platelet destruction. Shulman et al (1965) confirmed these findings
and reported that this anti-platelet factor was located in the IgG fraction.
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Three major organs of the reticuloendothelial system, the spleen, the liver and the bone marrow, are
critical in the pathological mechanisms of thrombocytopenia. The spleen is the most important site of
both antibody production and platelet destruction, because of its optimal circulation and platelet
sequestration. In patients with ITP, IgG production by the spleen has been shown to be increased
(McMillan et al, 1974). Mizutani et al (1991) have reported a significant increase in circulating and
splenic CD5+ B cells in these patients; the increase is correlated with the production of antiplatelet
antibodies. However, splenectomised patients may show persistent thrombocytopenia. The liver, also,
seems to play a pathological role, but probably only in severe forms of thrombocytopenia (Panzer et al,
1986; Najean et al, 1997).
Furthermore, platelet antibodies may have other effects. These antibodies may trigger platelet activation
via platelet FcRs. For instance, GP IIbIIIa-specific monoclonal antibodies have been suggested to activate
platelets via the platelet FcγRIIA (Anderson et al, 1991; Rubinstein et al, 1991; Berndt et al, 1993;
Deckmyn et al, 1998). Platelet antibodies may also affect the megakaryocytes in the bone marrow. Since
megakaryocytes carry the same antigens as mature platelets, platelet antibodies may interact with the
megakaryocytes leading to impaired platelet production. Patients with ITP and circulating GP Ib-specific
antibodies have been demonstrated to have megakaryocytes that are normal in number but smaller in size
than those with GP IIbIIIa-specific antibodies, suggesting that GP Ib-specific antibodies may impair
platelet production (Hasegawa et al, 1995). However, in the afore-mentioned study, GP-specific platelet-
associated IgG (PA-IgG) was not measured in these patients, although enzyme-linked immunosorbent
assay (ELISA) for PA-IgG was positive. Megakaryocyte-associated IgG has also been studied (Nagasawa
et al, 1995). Some patients with ITP (an estimated 20%) may additionally have impaired megakaryocytic
function and depressed platelet turnover (Ballem et al, 1987).
Other factors may also contribute to and be associated with the mechanisms of thrombocytopenia caused
by increased peripheral platelet destruction. Platelets normally express only major histocompatibility
complex class I molecules. Most studies on patients with ITP show no deviation in the frequency of HLA
class I A, B or C antigens (McMillan et al, 1980; Gaiger et al, 1994). However, increased incidences of
various HLA types have been reported to occur in these patients (Helmerhorst et al, 1982a; Gratama et
al, 1984; Porges et al, 1985; Mueller-Eckhardt et al, 1989; Nomura et al, 1998). HLA-B8 and DR3,
carrying DQA2.1 and DQB2.1, have been demonstrated to be overrepresented in patients with
rheumatoid arthritis and gold-induced thrombocytopenia or proteinuria than in patients with rheumatoid
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arthritis but without these side effects or in normal subjects (Singal et al, 1990). These inconsistencies
are probably partly explained by a significant heterogeneity among patients with autoimmune
thrombocytopenia.
There is also some evidence that genetic association of platelet alloantigens with autoimmune-mediated
thrombocytopenia may exist. Song et al (1997) demonstrated an association of the genotype HPA-5a5b
in GP Ia with autoimmune thrombocytopenia. Of the HPA-1, -2, -3 and -5 systems tested, HPA-2a allele
was shown to be associated with chronic refractory ITP (Thude et al, 1999). However, the evidence of
genetic association between autoimmune thrombocytopenia and the HPA system remains weak.
2.2.3. Different forms of thrombocytopenia
2.2.3.1. Idiopathic thrombocytopenia
Idiopathic thrombocytopenic purpura (ITP) is defined as isolated thrombocytopenia with no clinically
apparent associated conditions or other causes of thrombocytopenia. Laboratory findings show isolated
thrombocytopenia and the spleen size is normal. The incidence of ITP is estimated to be 10 to 125 new
cases per 1 000 000 persons per year (George et al, 1996). Some patients may be asymptomatic, but
usually the spontaneous bleeding manifestations, such as recurrent epistaxis, menorrhagia, mucosal
bleeding, or skin ecchymoses, petechiae and purpura are associated with counts of between 10 and 50
x 109/l (Doan et al, 1960). Patients with platelet counts of less than 10 x 109/l are likely to have mucosal
bleeding and a risk of central nervous system bleeding. The diagnosis of ITP is one of exclusion.
Recently, The American Society of Hematology established a practice guideline for diagnostic criteria
in ITP (George et al, 1996).
Among adults, ITP is typically a chronic disease lasting over 6 months, and spontaneous remission is
infrequent. It is most frequent in young women, 70% of female patients being under 40 years of age
(George et al, 1994). ITP in adults is a serious problem with a higher mortality rate than in children; the
overall mortality rate associated with ITP is about 4 to 5% (Berchtold & McMillan, 1989b; Stasi et al,
1995; George et al, 1996). Patients with chronic refractory thrombocytopenia are known to be clinically
heterogeneous. In adult patients, it is important to exclude other forms of immune-mediated
thrombocytopenia and, for instance, myelodysplastic syndrome, aplastic anaemia, chronic lymphocytic
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leukaemia and bone marrow infiltration as other causes of thrombocytopenia. The possibility of
hereditary thrombocytopenias, such as Bernard-Soulier syndrome or Wiskott-Aldrich syndrome, should
always be considered carefully, although hereditary thrombocytopenia may be difficult to distinguish
from ITP.
2.2.3.2. Drug-induced thrombocytopenia
In drug-induced thrombocytopenia, the platelet count decreases after ingestion of the drug and usually
starts to reverse shortly after cessation. The drugs most commonly associated with immune-mediated
thrombocytopenia include quinine, quinidine, gold and heparin (Rizvi et al, 1999). Early appearance of
thrombocytopenia may be seen, for instance, with sulphonamides, whereas a long induction period is
typical of gold salts. Severe thrombocytopenia with acute onset and a high frequency of haemorrhage may
be recorded during treatment with gold salts, sulphonamides, quinine and quinidine (Pedersen-Bjergaards
et al, 1998). Different pathophysiological mechanisms for drug-induced thrombocytopenia have been
proposed. A drug may conjugate with a platelet membrane protein and trigger production of hapten-
dependent antibodies, or it may induce the expression of a neoantigen subsequently recognised by
circulating antibodies only in the presence of the drug (Aster, 1999).
Gold-induced thrombocytopenia. Thrombocytopenia occurs in 1 to 3% of patients treated for rheumatoid
arthritis with either parenteral or oral forms of gold salts (Mettier et al, 1948; Kosty et al, 1989). Usually
the drug is taken over a period of 10 to 20 weeks before thrombocytopenia develops, but the onset may
also be abrupt (Klimiuk et al, 1987). The duration of the thrombocytopenia varies, and recovery usually
takes several weeks or months after cessation of the drug. In a few cases, the thrombocytopenia has
persisted for years, which is suggested to be due to the long half-life of gold salts. Thrombocytopenia
associated with gold therapy is suggested to be due to immune-mediated peripheral cell destruction
mechanisms. Platelet survival is shortened, and the megakaryocyte count in the bone marrow has been
demonstrated to be normal or increased (Levin et al, 1975; Klimiuk et al, 1987). Even IgG production
by splenic leucocytes has been demonstrated to be enhanced (Levin et al, 1975; von dem Borne et al,
1986a). However, gold-induced thrombocytopenia may be difficult to differentiate from
thrombocytopenia associated with the underlying disease.
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Quinidine/quinine-induced thrombocytopenia. Immune-mediated thrombocytopenia is a well-recognised
complication of quinidine and quinine therapy. The thrombocytopenia is usually severe and complicated
by bleeding. Bleeding symptoms appear acutely during quinidine therapy, which may have continued for
months or only for a few days. Quinidine-specific antibodies against platelets may be detectable in the
presence of the drug (Bolton, 1956; Kekomäki et al, 1980).
Heparin-induced thrombocytopenia (HIT). The potentially life-threatening, immune-mediated HIT may
be associated with both venous and arterial thrombotic events. It occurs in approximately 0.5 to 6.5% of
patients treated with unfractionated heparin (Warkentin et al, 1997). Generally, the diagnostic criteria
include both the clinical events and a positive laboratory test for heparin-dependent IgG. However, only
a minority of patients with HIT antibodies develop clinical HIT. In HIT, a macromolecular complex
composed of heparin (or low-molecular-weight-heparin or highly sulphated oligosaccharides) and platelet
factor 4 has been demonstrated to serve as an antigen for the immunoglobulin (Greinacher et al, 1994a
& b; Amiral et al, 1995). Interactions of the immunoglobulin with the platelet FcγRIIA, by cross-linking
of FcγRIIs, will trigger intravascular platelet activation and lead to increased destruction of peripheral
platelets (Anderson et al, 1991). Platelet FcR function (Warkentin et al, 1992) and density (Chong et al,
1993) may be correlated with the reactivity of platelets with HIT antibody. The distribution and
association of the functional polymorphism of platelet FcγRIIA has also been studied in HIT patients,
with inconsistent results.
2.2.3.3. Disease-related thrombocytopenia
Thrombocytopenia of autoimmune-mediated mechanisms has also been shown to be associated with
various disorders, especially with other autoimmune diseases. In collagenosis, for example, immune
thrombocytopenia is often present. In patients with systemic lupus erythematosus (SLE), mild
thrombocytopenia is common, and severe symptomatic thrombocytopenia occurs in approximately 5%.
Thrombocytopenia is even more common in patients with antiphospholipid antibodies (McNeil et al,
1991; Galli et al, 1994; Pujol et al, 1995).
Thrombocytopenia is often related to lymphoproliferative disorders. Patients with chronic lymphocytic
leukaemia may develop thrombocytopenia due to splenic sequestration, secondary to marrow packing,
but also due to immune destruction. Autoimmune-mediated thrombocytopenia has been estimated to
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occur in 2 to 3% of patients with chronic lymphocytic leukaemia (Diehl & Ketchum, 1998). In
lymphomas, thrombocytopenia may be related to marrow replacement, hypersplenism or an autoimmune
mechanism; purpura has been shown to occur in up to two-thirds of patients with non-Hodgkin
lymphoma or Hodgkin’s disease.
Thrombocytopenia may also exist in association with autoimmune haemolytic anaemia, as in Evans’
syndrome. In rheumatoid arthritis and inflammatory bowel disease, thrombocytopenia is mostly observed
as a side effect of therapy, but these diseases are rarely reported in association with immune-mediated
thrombocytopenia. The association of thyroid autoimmune disease and thrombocytopenia has also been
recognised; it has been suggested that over 10% of patients with autoimmune-mediated thrombocytopenia
might develop hyperthyroidism (Cordiano et al, 1998).
2.2.3.4. Thrombocytopenia in pregnancy
Thrombocytopenia may be observed in about 7% of pregnancies (McCrae et al, 1992). Mostly, the
aetiology of thrombocytopenia in pregnancy is chronic ITP, incidental thrombocytopenia of pregnancy
(gestational thrombocytopenia) or a complication of pregnancy. As a preliminary, preeclampsia or
eclampsia, disseminated intravascular coagulation, thrombotic microangiopathy and other complications
of pregnancy should always be excluded.
The most common cause of a low platelet count is incidental thrombocytopenia of pregnancy, accounting
for 75% of cases of maternal thrombocytopenia (Burrows & Kelton, 1993). It is characterised by
asymptomatic, mild (generally >50 x 109/l) thrombocytopenia, with no previous history. It is usually
present during late pregnancy, and resolves spontaneously postpartum, but may recur in subsequent
pregnancies.
Previously, ITP was estimated to affect only 1 to 2 out of every 10 000 pregnancies, but the most recent
reports suggest that the true incidence of ITP in pregnancy is higher, even 1 or 2 in every 1 000
pregnancies (McCrae et al, 1992; Burrows & Kelton, 1993; Sainio et al, 1998). ITP accounts for 3% of
all cases of thrombocytopenia at the time of delivery (Burrows & Kelton, 1993). The diagnosis of ITP
is especially difficult during pregnancy, since there are no particular features to distinguish it from the
incidental thrombocytopenia of pregnancy.
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2.2.3.5. Virus-induced thrombocytopenia
Viruses have been implicated in the aetiology of autoimmune diseases, and several mechanisms have
been suggested to induce autoimmune responses (Kaplan et al, 1992). The major mechanisms involved
in virus-induced immune thrombocytopenia are suggested to be disturbance in the host immune response,
molecular mimicry, production of anti-idiotype antibodies, enhanced expression of the major
histocompatibility complex molecules and changes in endogenous antigen. Platelet injury may also result
from antigen-antibody complexes originating from an immunological event essentially unrelated to the
platelet, i.e. the ’innocent bystander’ hypothesis.
In asymptomatic patients infected with the human immunodeficiency virus, the incidence of
thrombocytopenia may be 0 to 10%, whereas in symptomatic patients thrombocytopenia may be found
in up to 40% (Kaplan et al, 1992). Thrombocytopenia is a frequent manifestation in patients with rubella
(1/3000), whereas it seems to occur less frequently in measles and mumps (Nieminen, 1992). Mild to
moderate thrombocytopenia may be present in half the patients with Epstein-Barr virus infection.
Thrombocytopenia is also sporadically found in adult patients infected with cytomegalovirus. Acute
thrombocytopenia may also develop shortly after morbilli-mumps-rubella vaccination (Nieminen, 1992).
2.2.3.6. Cyclic thrombocytopenia
Cyclic thrombocytopenia is a rare disorder characterised by the alternation at regular intervals of
thrombocytopenia and thrombocytosis. It may be due to a variety of mechanisms, but a form with an
immunological mechanism has been suggested to exist. Patients are usually women whose oscillations
may correlate with the menstrual cycle (Tomer et al, 1989). Autoimmune antibodies have also been
reported to be involved in the aetiology of this disorder (Menitove et al, 1989).
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3. DETECTION OF PLATELET-ASSOCIATED ANTIBODIES
3.1. Flow cytometry as a diagnostic device
Flow cytometry allows rapid analytic measurement of large quantities of particles. A suspension of
fluorescence-labelled cells is injected into a flowing stream of fluid that passes through a focused laser
beam. Each cell transversing the laser beam will scatter light and generate emitted signals that are
collected through appropriately arranged filters and photodetectors. The light scatter signals, forward light
scatter (FSC) and side light scatter, provide information about cell size and cytoplasmic and nuclear
characteristics, respectively.
Different fluorescent signals may be collected in separate detection channels simultaneously. The
fluorescent dye used should absorb strongly at the wavelengths for which the excitation source is
available. The fluorescent labels most commonly used are fluorescein isothiocyanate, which gives green
fluorescence, and phycoerythin, which gives red-orange fluorescence. For example, in the detection of
platelet antibodies or platelet glycoproteins, the fluorescent dye may be coupled with an antibody. A
fluorescent dye, thiazole orange (TO), which gives green fluorescence, binds to both DNA and RNA and
forms a fluorescent nucleotide-reagent complex (Lee et al, 1986). It may be used to detect platelets with
an increased nucleic acid content, reticulated platelets (RP). For diagnostic purposes, flow cytometry
offers numerous possibilities.
3.2. Platelet-associated IgG (PA-IgG)
3.2.1. Platelet antibodies
In autoimmune thrombocytopenia, it is agreed that patients’ autologous platelets rather than circulating
antibodies should be studied when detecting platelet autoantibodies (Brighton et al, 1996; Kiefel et al,
1996; Berchtold et al, 1997; Warner et al, 1999). Normally, platelets are known to contain approximately
5 fg of IgG per platelet, of which only 1% is found on the platelet surface, and the majority of the total
platelet IgG is within secretory α-granules (George, 1991; LoBuglio et al, 1983; Leissinger & Stuckey,
1992). The increase in PA-IgG has been shown to be closely related to the reduced platelet count.
However, occasionally platelet autoantibodies may be present even if the platelet count is normal. PA-
IgG has been demonstrated to be inversely proportional to the platelet count and to the mean platelet
lifespan (Dixon et al, 1975; Mueller-Eckhardt et al, 1980; Panzer et al, 1986; Nieminen, 1992; Movahed
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Shariat Panahi et al, 1994). PA-IgG is known to consist mostly of subclasses IgG1 and IgG3 (von dem
Borne et al, 1980; Taaning & Petersen, 1988; Tijhuis et al, 1991).
Although in the diagnostics of autoimmune thrombocytopenia the detection of circulating platelet
antibodies is no longer considered sensitive or feasible, the knowledge previously gained, however, is
mostly about circulating antibodies. Detection of antibodies has revealed that GP IIbIIIa and GP IbIX are
the most immunogenic of the platelet glycoproteins (van Leeuwen et al, 1982; Beardsley et al, 1984;
Woods et al, 1984a & b; McMillan et al, 1987; Tomiyama et al, 1987 & 1989; Berchtold et al, 1989a;
Kokawa et al, 1993; Deckmyn et al, 1994; He et al, 1994; Stockelberg et al, 1995; Kiefel et al, 1996).
Furthermore, circulating platelet antibodies directed against GP IaIIa have been demonstrated
occasionally (Deckmyn et al, 1990; Godeau et al, 1997). Only a few data have been published on GP V
as a target for circulating platelet antibodies. Stricker & Shuman (1986) reported six patients with
quinidine-induced thrombocytopenia who had GP V-specific quinidine-dependent platelet antibodies.
The platelet antibodies were detected in serum by an immunoblotting assay with purified GP V as a
target. Bernard-Soulier platelets did not react with the antibody, the binding of which was Fab-mediated;
all this indicated that the target antigen was GP V. GP V-specific IgM antibodies characterised and
detected by an immunoblot analysis were reported in three children with clinically diagnosed varicella
zoster virus infection (Mayer & Beardsley, 1996).
In addition, a number of circulating antibodies directed against different platelet GPs have been
identified, for instance, in patients with human immunodeficiency virus and Epstein-Barr virus infections
(Winiarski, 1989; Gonzalez-Conejero et al, 1996). In patients with rubella, varicella zoster virus, human
immunodeficiency virus and Epstein-Barr virus infections, circulating autoantibodies and also PA-IgG
have been detected (Winiarski, 1989; Bettaieb et al, 1992; Kaplan et al, 1992; Gonzalez-Conejero et al,
1996).
Drug-dependent antibodies in sera of patients with quinidine- or quinine-induced thrombocytopenia have
mostly been reported to react with GP IIbIIIa or GP IbIX (Kunicki et al, 1978; van Leeuwen et al, 1982;
Christie et al, 1987; Visentin et al, 1991; Burgess et al, 1998). GP IbIX-specific drug-dependent
antibodies were associated with an acute, severe and quickly reversing type of thrombocytopenia, and
GP IIbIIIa-specific antibodies were associated with positivity for PA-IgG (Nieminen & Kekomäki, 1992).
In a few cases, gold-dependent antibodies have been demonstrated to be present (Kosty et al, 1989;
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Adachi et al, 1987), but they have mostly been undetectable (Stavem et al, 1968; Levin et al, 1975; von
dem Borne et al, 1986a; Klimiuk et al, 1987).
Platelet antibody targets have also been localised on unidentified proteins, glycolipids, glycosphingolipids
and phospholipids (van Vliet et al, 1987; Jouhikainen et al, 1990). A meta-analysis showed that 30% of
ITP patients have antiphospholipid antibodies (McNeil et al, 1991). Reid et al (1990) demonstrated that
the majority of normal sera contain IgG binding to protein bands at 90 to 95 kDa. Circulating antibodies
against internal platelet proteins, such as vinculin and talin (Tomiyama et al, 1992; Reid et al, 1993), and
also against cytoskeletal tropomyosin (Hou et al, 1996) have been demonstrated in both patients and
controls. Platelet granule membrane protein of 140 kDa, GMP140 (CD62) has also been reported to be
a target (Bierling et al, 1994). The pathogenetic significance of antibodies against relatively inaccessible
targets remains to be determined. Thus, the importance of circulating antibodies should be interpreted
with caution.
3.2.2. Detection of PA-IgG
Direct assays measure platelet-bound immunoglobulins, antibodies on the surface of intact platelets. For
the first time, the quantitative antiglobulin consumption assay allowed the direct determination of PA-IgG
(Dixon et al, 1975). In this test, platelet-bound IgG was determined from the consumption of anti-IgG,
as measured by inhibition of the lysis of IgG-coated sheep red cells in the presence of complement.
However, in the detection of PA-IgG, the platelet immunofluorescence test (PIFT) and the ELISA have
been applied widely (von dem Borne et al, 1978; Lin et al, 1990; Table 3). In PIFT, a paraformaldehyde-
fixed platelet suspension is incubated with fluorescence-labelled anti-human antibody and analysis of the
fluorescence may be performed with flow cytometry. There is a wide variety of different ELISA methods.
In general, a platelet suspension is attached to microtitre wells as a monolayer or as a detergent lysate,
and antibodies, tagged with peroxidase or alkaline phosphatase serve as ligands. Moreover, in the platelet
radioactive antiglobulin test, radioactive 125I-labelled anti-IgG is bound to the IgG on the platelet surface,
and the amount of radioactivity is measured to obtain the amount of PA-IgG (Soulier et al, 1975;
Mueller-Eckhardt et al, 1980; Table 3).
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Table 3. Studies on platelet-associated IgG (PA-IgG)
Patients PA-IgG
Method Diagnosis n n (%) Reference
PIFT ITP 80 55 (69) von dem Borne et al, 1980
PRAT TP 176 94 (53) Mueller-Eckhardt et al, 1980
QACA Drug-induced TP 18 18 (100) Kelton et al, 1981
PIFT Immune TP
Disease-related TP
215
142
195 (91)
136 (96)
Helmerhorst et al, 1982b
PIFT
(direct eluate)
RA with gold therapy 13 13
13 eluate
von dem Borne et al, 1986a
PIFT ITP
TP
75
194
63 (84)
153 (79)
von dem Borne et al, 1986b
PRAT ITP 17 11 (65) Panzer et al, 1986
FCM ITP 44 33 (75) Rosenfeld et al, 1987a
PRAT Immune TP
Non-immune TP
67
55
60 (90)
4 (7)
Court et al, 1987
ELISA TP (children) 17 16 (94) Taaning & Petersen, 1988
PIFT ITP 109 88 (81) Nieminen, 1990
Immunobead
assay
ITP children
Non-TP children
36
31
26 (72)
15 (48)
Imbach et al, 1991
PIFT Quinidine-induced TP 14 7 (50) Nieminen & Kekomäki, 1992
FCM Immune TP
Non-immune TP
16
9
12 (75)
2
Christopoulos et al, 1993
FCM SLE
ITP
25
65
11 (44)
45 (69)
Kurata et al, 1993
ELISA ITP 33 28 (85) Movahed Shariat Panahi et al, 1994
ELISA ITP 30 11 (37) Nagasawa et al, 1995
PRAT Chronic liver disease 33 17 (52) Pereira et al, 1995
CELIA Immune TP
Non-immune TP
81
46
60 (74)
34 (74)
Brighton et al, 1996
FCM, ELISA HIV 45 19 (42) FCM
16 (36) ELISA
Gonzalez-Conejero et al, 1996
PRAT MDS 30 21 (70) Hebbar et al, 1996
Immunoradio-
metric assay
ITP
Non-immune TP
49
32
38 (78)
26 (81)
Warner et al, 1999
CELIA: competitive ELISA; ELISA: enzyme-linked immunosorbent assay; FCM: flow cytometry, immuno-fluorescence
assay; HIV: human immunodeficiency virus; ITP: idiopathic thrombocytopenic purpura; MDS: myelodysplastic
syndrome; PIFT: platelet immunfluroescence test; PRAT: platelet radiolabelled antiglobulin test; QACA: quantitative
antiglobulin consumption assay; RA: rheumatoid arthritis; TP: thrombocytopenia
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The direct PIFT has been considered especially sensitive; 70 to 85% of patients with ITP have been
demonstrated to have positive PA-IgG with direct PIFT (Table 3). Christopoulos et al (1993) used a
similar assay based on flow cytometry, and demonstrated positive values of PA-IgG in 75% (12/16) of
patients suggested to have immune thrombocytopenia and in 2 of 9 patients with suspected non-immune
thrombocytopenia (Table 3). Helmerhorst et al (1980) compared the three assays, PIFT, the quantitative
antiglobulin consumption assay and the platelet radioactive antiglobulin test, for the detection of PA-IgG.
They found PIFT to be the most sensitive technique. Yet, in the diagnosis of autoimmune
thrombocytopenia detection of PA-IgG suffers from lack of specificity (von dem Borne et al, 1986b;
Rosenfeld et al, 1987a). However, complications in the measurement of platelet antibodies may be caused
by naturally occurring antibodies, internal platelet IgG and aggregated IgG of immune complexes bound
to the platelet or antibodies against platelet cryptantigens (Rosenfeld et al, 1985; Muniz-Diaz et al, 1995).
3.2.3. PA-IgG in patients of different groups
PA-IgG has been detected on the platelet membrane in 75 to 90% of patients with ITP (Dixon et al, 1975;
LoBuglio et al, 1983; McMillan et al, 1987; Tani et al, 1989; Berchtold & Wenger 1993). Some other
studies on PA-IgG are listed in Table 3. However, the specificity of PA-IgG in the diagnosis of ITP is
less than 30% (Mueller-Eckhardt et al, 1980; Kelton et al, 1982).
Furthermore, PA-IgG is often present in gold-induced thrombocytopenia (Kelton et al, 1981; von dem
Borne et al, 1986a; Adachi et al, 1987; Kosty et al, 1989), although its GP specificity has not been
determined. Moreover, increased PA-IgG has been reported in varying proportions of patients with
thrombocytopenia that is presumably not of immunological origin (Helmerhorst et al, 1982b; Kelton et
al, 1982). With the quantitative platelet radioactive antiglobulin test, Mueller-Eckhardt et al (1980)
demonstrated large amounts of PA-IgG in patients with systemic blood diseases, such as leukaemias or
lymphomas and hepatic or infectious disorders. Warner et al (1999) reported PA-IgG by
immunoradiometric assay in 78% (of 49) patients with ITP, but also in 81% (of 32) patients with non-
immune thrombocytopenia, such as pancytopenia secondary to chemotherapy, aplastic anaemia, Bernard-
Soulier syndrome, incidental thrombocytopenia of pregnancy, platelet function defect, human
immunodeficiency virus and hepatitis. Occasionally in the case of hereditary thrombocytopenia, PA-IgG
may be detectable, probably because of the platelet membrane abnormalities.
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Platelet autoantibodies of the IgM and IgA classes have been suggested to play only a minor role in the
pathogenesis of thrombocytopenia caused by increased platelet destruction. Yet, autoantibodies of all
three Ig classes have been reported to correlate with the platelet count (Kokawa et al, 1991; Movahed
Shariat Panahi et al, 1994). With the PIFT PA-IgG, PA-IgM and PA-IgA were detected in 92%, 42% and
9% of patients with ITP, respectively (von dem Borne et al, 1986b). Kiefel et al (1996) detected GP-
specific PA-IgG, PA-IgM and PA-IgA in 46%, 15% and 3% of patients with autoimmune-mediated
thrombocytopenia. In a few cases, PA-IgM and PA-IgA may offer additional information, but their
presence is not yet fully understood.
3.3. GP-specific PA-IgG
3.3.1. Detection of GP-specific PA-IgG
Different applications of monoclonal antibodies specific for specific platelet proteins have made it
possible to define the platelet antibody targets clearly. Generally in antigen capture assays, platelet
antigens are solubilised and immobilised on plastic wells prior to exposure to the antibody. Woods et al
(1984a) used a microtitre well assay, in which platelet GPs were fixed to microtitre plates with
monoclonal antibodies. The wells were exposed to the patient’s serum and binding of the antibody
directed against GP was determined with 125I-labelled anti-human IgG. Later on, monoclonal antibody-
specific immobilisation of platelet antigens (MAIPA) allowed detection of the GP specificity of platelet
antibodies (Kiefel et al, 1987).
The GP specificity of PA-IgG may be detected with different direct methods, such as MAIPA,
immunobead assay, immunoprecipitation and modified antigen capture ELISA (MACE; McMillan et al,
1987; Tomiyama et al, 1990; Kiefel et al, 1991; Berchtold & Wenger, 1993; Berchtold et al, 1997; Fig
4). In the antigen capture assay, platelet-specific monoclonal antibodies capture an epitope carrying
molecules from a platelet lysate onto a solid matrix, and their ligands are labelled. The direct modified
antigen capture assay, based on this principle, is similar to MAIPA and the immunobead assay methods
(Kurata et al, 1993; Pereira et al, 1995; Berchtold et al, 1997). The MAIPA and the immunobead assay
are the tests most widely used for the measurement of GP-specific PA-IgG (Table 4).
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Fig 4. Platelet glycoprotein (GP)-specific assays for the direct detection of GP-specific platelet-associated IgG (PA-
IgG). Washed platelets with GP-specific PA-IgG (step 1) are lysed (step 2) and the GP of interest is immobilised
on a plastic surface using a monoclonal antibody (moAb) or an Ab specific against human IgG, (Anti-IgG; step 3).
In contrary, in MAIPA, the sensitisation with moAb is performed prior the cell lysis. Anti-mouse: Ab against mouse
IgG; AutoAb: platelet-specific autoAb; MACE: modified antigen capture ELISA; MAIPA: monoclonal antibody-
specific immobilization of platelet antigens.
In the direct immunobead assay, the patient’s washed platelets are solubilised and the centrifuged
supernatant containing the immune complexes is captured on a plastic surface using a murine platelet GP-
specific monoclonal antibody (Fig 4; McMillan et al, 1987; Berchtold et al, 1989b; Tani et al, 1989;
Berchtold et al, 1997). Either polystyrene beads or microtitre wells may be used as a plastic surface. In
contrast to the MAIPA, in which the patient’s platelets are first incubated with a monoclonal antibody,
solubilisation is performed prior to incubation.
In the direct MAIPA (Kiefel et al, 1991 & 1996), washed platelets are incubated with monoclonal
antibody. After solubilisation, incubation is performed on a plastic surface coated with anti-mouse Ig,
and the captured complex is detected with enzyme-labelled anti-human IgG (Fig 4). Different forms of
the MAIPA assay have already been introduced (Kiefel, 1992). The MAIPA assay may be considered
both sensitive and reliable, although it has certain limitations, such as false-negative results due to
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epitope competition between human antibodies and monoclonal antibodies (Morel-Kopp et al, 1996). On
the one hand, selection of the monoclonal antibodies used and, on the other hand, lack of specific
monoclonal antibodies are also important factors restricting the value of MAIPA. Brighton et al (1996)
used the direct MAIPA for the detection of GP IIbIIIa- and GP IbIX-specific PA-IgG in randomly chosen
patients with thrombocytopenia initially diagnosed to be either immune (n=94; ITP, disease-related and
drug-induced thrombocytopenia) or non-immune (n=53; aplastic anaemia, neoplastic infiltration, chronic
liver disease, drug-associated thrombocytopenia). As reference methods for PA-IgG, they used both
ELISA and a modified competitive ELISA, and they observed a sensitivity of 51% and a specificity of
80% with MAIPA.
Both the direct MAIPA and the direct immunobead assay are sensitive, reproducible and consistent in
their results. The first international study to compare methods for the detection of GP-specific PA-IgG
was reported in 1997 (Berchtold et al). Blinded samples, supplied by participants, were centrally
aliquoted and distributed. Eight participating laboratories used either MAIPA, the immunobead assay or
MACE to detect GP-specific PA-IgG. It was concluded that good agreement was obtained between the
laboratories in the detection of GP-specific PA-IgG. Crossley et al (1997) compared the MAIPA and
immunobead assays for the detection of GP IIbIIIa-specific PA-IgG. The study showed MAIPA assay
to be more reproducible than the immunobead assay (9/10 vs. 6/10 identical results repeatedly parallel,
respectively), and the sensitivities (although tested with titrated positive serum) were similar. Recently,
MACE and MAIPA were compared for the detection of GP IIbIIIa-specific PA-IgG of 81 samples from
thrombocytopenic patients (Warner et al, 1999). The GP-specific assays were found to be alike in
sensitivity (39%) and specificity (91%). In agreement, direct GP-specific assays may complement PA-
IgG measurements in the classification of autoimmune-mediated thrombocytopenia.
Direct platelet eluates also allow detection of GP-specific PA-IgG and the results obtained are in good
agreement with direct tests; in 82 ITP patients, the antibodies were shown to have specificities against
both GP IIbIIIa (in up to 90%) and IbIX (less than 20%; Kiefel et al, 1996; Hürlimann-Forster et al, 1997;
Table 4). Nevertheless, the detection of direct platelet eluates requires a selected patient population with
a relatively high platelet count.
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Table 4. Studies on glycoprotein (GP)-specific platelet-associated IgG (PA-IgG)
Patients GP-specific PA-IgG n (%)
Method Diagnosis n IIbIIIa IbIX IIbIIIa/IbIX Reference
Immunobead assay ITP 28 13 (46) 8 (29) 21 (75) McMillan et al,
1987
Immunobead assay Disease-related TP 19 9 (47) 2 (11) Berchtold et al,
1989c
Immunoprecipitation ITP 6 4 Tomiyama et al,
1990
Immunobead assay ITP children
ITP adults
41
16
40 (98)
14 (88)
1 (2)
2 (13)
Imbach et al, 1991
MAIPA Immune TP 29 21 (72) 22 (28) 14 (48) Kiefel et al, 1991
ELISA ITP 71 25 (35) 10 (14) Kokawa et al, 1991
Immunobead assay ITP
In remission
53
17
26 (49)
10 (59)
6 (11)
3 (18)
7 (13)
4/17 (24)
Berchtold &
Wenger, 1993
MACE (direct eluate) ITP 7 6 Kurata et al, 1993
MACE Chronic liver
disease
36 3 (8) 10 (28) 6 (17)
19 (58)
Pereira et al, 1995
MAIPA Immune TP
Non-immune TP
81
51
19 (23) 5 (6) 16 (20)
11 (22)
Brighton et al,
1996
MAIPA Immune TP
Non-immune TP
78
40
36 (46)
0
Kiefel et al, 1996
PAICA ITP 20 8 (40) 2 (10) 2 (10) Macchi et al, 1996
Immunobead assay,
MAIPA, MACE
TP 22 18 (82) 17 (77) Berchtold et al,
1997*
Immunobead assay,
MAIPA
ITP 40 8 (20) Crossley et al,
1997
ELISA
(direct eluate)
ITP 82 75 (92) 14 (17) Hürlimann-Forster
et al, 1997
MAIPA, Antigen
capture assay
ITP
Non-immune TP
49
32
19 (39)
3 (9)
19 (39)
3 (9)
Warner et al, 1999
* A total of eight participating laboratories, taken as positive when reported positive by >2 laboratories.
ELISA: enzyme-linked immunosorbent assay; ITP: idiopathic thrombocytopenic purpura; MACE: modified antigen
capture ELISA; MAIPA: monoclonal antibody-specific immobilization of platelet antigens; PAICA: platelet-
associated IgG characterization assay; PIFT: platelet immunofluorescence test; TP: thrombocytopenia.
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3.3.2. Antigens and epitopes of PA-IgG
Studies on GP IIbIIIa- and IbIX-specific PA-IgG are summarised in Table 4. As specific autoepitopes,
PA-IgG has also been determined to be directed against cation-dependent conformational antigens
(Fujisawa et al, 1993). Using recombinant peptides, one patient with GP IIbIIIa-specific PA-IgG was
demonstrated to have antibodies binding to the region of amino acids 350-550 of GP IIIa. Kosugi et al
(1996b) were able to recognise cation-dependent regions of GP IIbIIIa as autoantigenic targets of PA-IgG.
The presence of GP IV-specific PA-IgG was detected with the immunobead assay in one patient with a
bleeding disorder who also had both GP IIbIIIa- and GP IaIIa-specific autoantibodies (Beer et al, 1993).
3.3.3. GP-specific PA-IgG in patients of different groups
Several studies have shown that direct measurements of GP-specific platelet antibodies may be used in
the classification of autoimmune thrombocytopenia (Table 4). McMillan et al (1987) demonstrated PA-
IgG in 75% of patients with ITP, 62% of whom had GP IIbIIIa and 58% GP Ib specificity. Similarly, Tani
et al (1989) found GP IIbIIIa- and/or GP IbIX-specific PA-IgG in 80% of patients with ITP. Detection
of the glycoprotein (GP) specificity of platelet-associated IgG (PA-IgG) has been suggested to improve
the specificity of tests aimed at the detection and classification of autoimmune thrombocytopenia.
GP-specific PA-IgG has been detected not only in patients with ITP, but also in patients with disease-
related thrombocytopenia, i.e. SLE, chronic lymphocytic leukaemia or chronic liver disease. Berchtold
et al (1989c) were able to detect GP IIbIIIa- and GP IbIX-specific PA-IgG in 60% of patients with
disease-related thrombocytopenia, such as chronic lymphocytic leukaemia, Hodgkin’s disease, idiopathic
pulmonary fibrosis, mixed connective tissue disease and Sjögren's syndrome.
In patients with SLE, the PA-IgG of platelet eluates has been shown to bind specifically to GP IIbIIIa,
and the presence of PA-IgG was significantly associated with thrombocytopenia and disease activity
(Kurata et al, 1993). Fabris et al (1994) demonstrated PA-IgG by direct PIFT in 6 of 10 patients with SLE
and in 5 of 8 patients with primary anti-phospholipid syndrome. In another study of 90 patients with SLE,
the prevalence of PA-IgG was also high (62%; Pujol et al, 1995).
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A high prevalence of GP-specific PA-IgG has also been observed with MACE in patients with chronic
liver disease (Pereira et al, 1995; Table 4). Using a direct platelet eluate, GP IIbIIIa-specific antibodies
were demonstrated in a patient with primary biliary cirrhosis (Panzer et al, 1990). Also using direct
platelet eluates, Bettaieb et al (1992) demonstrated GP IIbIIIa-specific PA-IgG in patients with human
immunodeficiency virus. Direct MAIPA was positive in 5 of 8 patients with ITP, as well as in 4 of 8
patients with disease-related thrombocytopenia, such as SLE, and also in 2 of 4 patients with systemic
autoimmune disease without thrombocytopenia (Cordiano et al, 1996).
Brighton et al (1996) reported GP IIbIIIa- and IbIX-specific PA-IgG by MAIPA in 49% (40/81) of
patients with immune thrombocytopenia (ITP or secondary immune) and in 22% (11/51) of patients with
an initial diagnosis of non-immune thrombocytopenia, including diagnoses such as non-Hodgkin’s
lymphoma, chronic liver disease, aplastic anaemia, leukaemia, multiple myeloma and disseminated
intravascular coagulation. Warner et al (1999) reported GP IIbIIIa-specific PA-IgG detected by MACE
and MAIPA in 39% (of 49) patients with ITP and also in three (chronic hepatitis and two with the
myelodysplastic syndrome) of 32 patients with non-immune thrombocytopenia. Thus, detection of GP-
specific PA-IgG seems to improve our understanding of the nature of platelet antibodies in the different
forms of autoimmune thrombocytopenia and in forms of thrombocytopenia initially considered non-
immune.
4. PLATELET Fcγ RECEPTOR TYPE IIA (FcγRIIA)
FcγRIIA is the only FcγR expressed on platelets (Rosenfeld et al, 1985; Cassel et al, 1993; Wu et al,
1996). The number of FcγRIIA molecules on the platelet surface may vary considerably between
individuals; the number of binding sites per platelet has been suggested to vary between 600 and 8000
(Karas et al, 1982; Rosenfeld et al, 1987b; Anderson et al, 1995; Table 1). The average number of
receptors per platelet has been shown to be stable. For complexed IgG, the binding affinity of platelet
FcγR has been shown to be low (Kekomäki & Myllylä, 1979). Platelet FcγRIIA has been demonstrated
to be topographically and probably also functionally associated with GP IIbIIIa, and GP IIbIIIa-specific
monoclonal antibodies are suggested to activate platelets via FcγRIIA (Berndt et al, 1993; Rubinstein et
al, 1991).
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The only known functionally important genetic polymorphism of FcγRIIA is the polymorphism H131R,
which has been shown in a three-dimensional computer-based model to be located near the potential IgG-
binding site (Hulett et al, 1994). The genetic polymorphism of FcγRIIA in amino acid position 131 results
from a single base substitution (A/G) at nucleotide 494 in the second extracellular domain of the receptor
(Clark et al, 1989; Warmerdam et al, 1990). In the early studies, different affinity patterns of the
structural polymorphism were demonstrated in monocytes (Anderson et al, 1987). The monoclonal
antibody 41H16, directed against FcγRII, binds strongly only to the arginine 131 (R131) form of the
FcγRIIA protein and thus discriminates between these two polymorphic forms. The histidine 131 (H131)
allele (494A) is characterised by high affinities for human IgG2 and IgG3, whereas the R131 allele
(494G) has a low affinity for human IgG2 (Warmerdam et al, 1991; Parren et al, 1992). IgG1 binds
equally well to platelets expressing any of the FcγRIIA phenotypes (Warmerdam et al, 1991; Osborne
et al, 1994).
4.1. Typing of FcγRIIA polymorphism H131R
Several methods have been introduced for the detection of FcγRIIA polymorphism. Functional assays
were applied first to determine the different forms of FcγRIIA (Rosenfeld et al, 1987b). Phenotyping of
FcγRIIA is possible with monoclonal antibodies (Salmon et al, 1992; Sanders et al, 1994; Duits et al,
1995). At present, detection of FcγRIIA polymorphism is most commonly performed by genotyping.
Clark et al (1991) were the first to use selective oligonucleotide primers to amplify a DNA fragment
encoding the FcγRIIA polymorphism site and perform DNA sequencing. Both automated DNA sequence
analysis and a single-strand conformation polymorphism assay have been used after polymerase chain
reaction (PCR) amplification of a 278-base pair (bp) FcγRIIA-specific fragment (Reilly et al, 1994). The
method used after FcγRIIA-specific PCR amplification, allele-specific oligonucleotide hybridisation is
probably the most widely used, since it was first introduced as an easily adaptable genotyping method
(Osborne et al, 1994; Brandt et al, 1995; Burgess et al, 1995; Salmon et al, 1996; Williams et al, 1998).
Bachelot et al (1995) used denaturing gradient gel electrophoresis and DNA sequencing of single-strand
templates. De Haas et al (1995) used the 1000-bp fragment product of the initial FcγRIIA-specific PCR
amplification (Osborne et al, 1994) in a nested PCR method, in which a sense mismatch primer created
a novel potential restriction site.
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A more rapid genotyping method, allele-specific restriction enzyme digestion, requires only one step PCR
to introduce a potential restriction site (Jiang et al, 1996; Arepally et al, 1997; Atsumi et al, 1998;
Lehrnbecher et al, 1999). A recently developed rapid genotyping method, using allele-specific primers,
seems to give reliable results when compared with allele-specific oligonucleotide hybridisation (Flesch
et al, 1998). Thus, several methods have been applied for FcγRIIA genotyping, the restriction enzyme
digestion methods being the most reliable and easily adapted methods. Recently developed rapid methods
will have an advantage over the earlier ones.
4.2. The clinical significance of platelet FcγRIIA polymorphism H131R
The HH131 genotype of FcγRIIA has been associated with enhanced clearance of immune complexes
compared with HR131 and RR131; both polymorphonuclear cells and monocytes from HH131 donors
bound and internalised human IgG2-coated erythrocytes efficiently, whereas phagocytes from RR131
donors did so poorly (Salmon et al, 1992). Although the H131R polymorphism has been shown to affect
the ligand binding properties of the receptor for the different IgG subclasses, whether the H131R
polymorphism affects the level of PA-IgG on circulating platelets from thrombocytopenic patients has
not been studied. Since FcγRs have been suggested to play a role in causing susceptibility to or
modification of some diseases, distribution of FcγRIIA polymorphism has also been studied widely in
different groups of patients with SLE, HIT, myasthenia gravis, chronic granulomatous disease, sickle cell
anaemia or bacterial infections (Lehrnbecher et al, 1999; Table 5). It seems that the R131 allele may have
a potential role related to the nephritis in SLE (Duits et al, 1995; Salmon et al, 1996). The role of
FcγRIIA polymorphism in HIT continues to be inconsistent (Table 5). In 29 patients with refractory ITP
the distributions of FcγRIIA polymorphism showed skewness towards the RR131 genotype (Table 5).
Thus, the clinical significance of the FcγRIIA polymorphism in the different immune-mediated
thrombocytopenic conditions needs further evaluation.
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Table 5. Distribution of genetic polymorphism H131R of FcγRIIA in patients with different diagnoses.
Diagnosis Controls Patients
(ethnic origin) n H131 R131 n H131 R131 HH131 (%) HR131 RR131 Reference
SLE (Caucasian) 259 0.45 0.55 215 0.44 0.56 21 45 33 Botto et al, 1996
SLE 100 0.52 0.48 214 0.40 0.60 17 45* 37* Salmon et al, 1996
SLE (Caucasian) 187 0.51 0.49 108 0.54 0.46 37 34 29 Manger et al, 1998
SLE nephritis 100 0.52 0.48 103 0.35 0.65 12 47 42* Salmon et al, 1996
SLE 69 0.58 0.42 95 0.45 0.55 19 53 28 Duits et al, 1995
SLE (British) 66 0.47 0.53 81 0.43 0.57 12 60 27 Smyth et al, 1997
SLE (Afro-Caribbean) 77 0.45 0.55 70 0.38 0.62 11 53 36 Botto et al, 1996
SLE nephritis 69 0.58 0.42 50 0.38 0.62 14 48 38* Duits et al, 1995
SLE (Chinese) 49 0.69 0.31 46 0.63 0.36 39 50 11 Botto et al, 1996
SLE (Greek) 52 0.62 0.38 42 0.52 0.48 33 38 29 Smyth et al, 1997
HIT 256 0.54 0.46 389 0.46 0.54 20 53 27* Carlsson et al, 1998
HIT 100 0.44 0.56 96 0.56 0.44 34* 43 23 Brandt et al, 1995
HIT 264 0.47 0.53 84 0.57* 0.44 36 41 23 Denomme et al, 1997
HIT 102 0.47 0.53 36 0.49 0.51 22 53 25 Arepally et al, 1997
HIT 218 0.56 0.44 25 0.52 0.48 20 64 16 Bachelot-Loza et al, 1998
HIT (Caucasian) 22 0.39 0.61 19 0.61 0.39 21* 79* 0 Burgess et al, 1995
Refractory ITP 61 0.53 0.47 29 0.31 0.69 10 42 48* Williams et al, 1998
Apl syndrome 41 0.50 0.50 100 0.46 0.54 21 50 29 Atsumi et al, 1998
* significantly overrepresented according to the original reference, as compared with the controls.
Apl: antiphospholipid; HIT: heparin-induced thrombocytopenia; ITP: idiopathic thrombocytopenic purpura; SLE: systemic lupus erythematosus.
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5. DETECTION OF RETICULATED PLATELETS (RP)
Platelets with an increased nucleic acid content are believed to be young platelets, RP. In the circulation
RP are suggested to reflect megakaryocyte stimulation and platelet production. RP can be detected with
thiazole orange (TO; Lee et al, 1986) staining combined with flow cytometric analysis of the fluorescence
(FL; Kienast & Schmitz, 1990). The TO labelling has been shown to be sensitive to ribonuclease
(RNAase), and thus may be considered to be due to an increased RNA content (Ault et al, 1992).
5.1. Measurement of RP
One of the problems in direct measurement of TO-stained platelets is to define a threshold gate for
positivity. Some studies on RP are summarised in Table 6. Ault et al (1992) defined the proportion of
RP by drawing an arbitrary line using the FSC versus FL plot with the same slope as the platelet cluster
to segregate 99% of the normal platelets below the line. The positioning of the line was shown to be
consistent after RNAase treatment. An automated measurement of RP was based on this same principle
(Watanabe et al, 1995). Bonan et al (1993) used autologous erythrocyte TO fluorescence in whole blood
as an internal standard for TO fluorescence of platelets. Rinder et al (1993) used a threshold defined by
normal control values, i.e. the mean for a normal control sample + 2 standard deviations (SD), as a limit
for TO-positive platelets. Unstained control samples have also been used in setting the gate of positivity
(Romp et al, 1994; Richards & Baglin, 1995; Tàssies et al, 1995). Recently, lyophilised platelets were
also introduced as control samples (Saxon et al, 1998). However, there is no internationally agreed
system of standardisation or consensus for acquisition of data or for their analysis.
5.2. RP in healthy controls and patients
In normal adults, the range of RP has been reported to vary greatly between 1 and 20% including inter-
individual and inter-assay variation as well as variation between the results obtained in different
laboratories (Table 6). Theoretically, a normal RP value would be less than 10%, considering that the
majority of the RNA is degraded within 24 h, and that platelets have a normal mean lifespan of 7 to 10
days (Ingram & Coopersmith, 1969; Ault et al, 1995; Dale et al, 1995). In healthy controls, Bonan et al
(1993) have demonstrated a difference in RP percentage between healthy males and females, the
proportion of RP being higher among women, although such a sex-related difference has never
subsequently been confirmed (Kienast & Schmitz, 1990; Watanabe et al, 1995).
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Table 6. Different ways of estimating the degree of fluorescence of TO-stained platelets (reticulated
platelets): control samples and ways of setting the threshold for positivity.
Controls
Sample
Analysis of TO
fluorescence*
Threshold for
positivity (control) n
RP (%)
Mean+SD
RP range
(%) Reference
Blood FL histogram unstained sample,
normal 1%
50 8.6+2.8 2.8-15.8 Kienast & Schmitz,
1990
PRP FSC vs. FL plot RNAase treatment,
normal 1% †
69 0.9+0.1 Ault et al, 1992
PRP FL histogram PE,
erythrocyte control
14 male
15 female
3.64+2.10
5.79+2.22
Bonan et al, 1993
PRP FL histogram normal 1%,
mean+2SD
40 2.9+2.2 Rinder et al, 1993
PRP FL histogram normal 1%,
mean+2SD
31 pregnant,1st
22, 2nd
29, 3rd trimester
4.9+4.2
2.5+1.7
5.0+4.2
Rinder et al, 1994
PRP FL histogram unstained sample,
erythrocyte control
20 4.2+1.9 Romp et al, 1994
PRP FL histogram unstained sample,
normal 1%
41 Richards & Baglin,
1995
Blood FSC vs. FL plot RNAase treatment,
normal 1%
0.98+0.41 Watanabe et al, 1995
PRP FL histogram PE,
erythrocyte control
39 neonates,
>36
25, 30-36
25, <30 weeks
4+2.4
4.6+1.7
8.8+5.1
2-12
2-7
3-6
Peterec et al, 1996
Blood FL histogram RNAase treatment,
PE, normal 2%
22 11.6+4.2 Chavda et al, 1996
Blood FSC vs. FL plot normal 1%, PE,
unstained sample
40 2.17+0.90 Koike et al, 1998
Blood FSC vs. FL plot PE, normal 1%,
lyophilized
platelets
27 7.9+2.9 2.8-13.9 Saxon et al, 1998
* FL histogram: TO positivity presented as a histogram; FSC vs. FL plot: TO positivity presented as a plot of FSC vs. FL.
† normal n%: <n% of TO positivity was considered normal.
Blood: whole blood sample; FL: fluorescence intensity for TO positivity; FSC: forward light scatter; PE: phyco-erythrin-
conjugated antibody against platelet glycoprotein to demonstrate platelets; PRP: platelet-rich plasma; RNAase:
ribonuclease to demonstrate RNA-specific binding of TO; TO: thiazole orange.
42
Pregnant women in the third trimester and non-pregnant women have been reported to have similar
percentages of RP, in spite of a significant fall in the platelet count in the third trimester of pregnancy
(Rinder et al, 1994). The fall in the platelet count has been postulated to be due either to down-regulation
of thrombopoiesis or to dilutional aetiology of thrombocytopenia. Significantly higher percentages of RP
were reported in four women with pre-eclampsia at 26 gestational weeks, before the onset of any clinical
signs (13.9 + 11.2% vs. 5.8 + 2.2% in controls; Rinder et al, 1994).
Patients with immune thrombocytopenia have been demonstrated to have higher proportions of RP in
the circulating blood than controls or patients with thrombocytopenia due to insufficient thrombopoiesis.
Kienast & Schmitz (1990) studied thrombocytopenic patients, 21 with a normal bone marrow and 23 with
decreased platelet production, and found a significantly higher RP% in the patients with sufficient
thrombopoiesis. Ault et al (1992) investigated RP and PA-IgG in 229 patients with thrombocytopenia.
Patients with a normal level of PA-IgG had a normal proportion of RP, whereas, in those who were
positive for PA-IgG, the absolute number of RP was increased if the thrombocytopenia was moderate
(60-100 x 109/l) but was normal or decreased if the thrombocytopenia was severe. Richards & Baglin
(1995) studied 79 thrombocytopenic patients (25 with immune thrombocytopenia and a normal bone
marrow, 31 with bone marrow aplasia, and seven with consumptive coagulopathy) and found that the
patients with increased peripheral platelet destruction had a higher RP% than those with decreased
platelet production. Similar results have been reported by other groups (Watanabe et al, 1995; Chavda
et al, 1996; Peterec et al, 1996; Koike et al, 1998; Saxon et al, 1998; Stohlawetz et al, 1999). It has even
been postulated that the RP% alone has an even better predictive value than PA-IgG measured with flow
cytometry for the diagnosis of autoimmune thrombocytopenia (Rinder et al, 1993). Thus, TO positivity
has been suggested to serve as a marker of an increased proportion of RP.
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AIMS OF THE STUDY
The aims of this study were to develop laboratory methods for investigating the factors potentially
affecting the pathogenesis of autoimmune thrombocytopenia and to subclassify thrombocytopenic
patients into different groups with the following specific objectives:
• to test for the presence of platelet-associated antibodies (PA-IgG) in patients with thrombocytopenia,
• to study the glycoprotein (GP) IIbIIIa and IbIX specificity of the platelet antibodies in patients with
PA-IgG,
• to study whether the platelet GP V plays a role as a target antigen in patients with thrombocytopenia,
• to determine the polymorphism H131R of the platelet Fcγ receptor in patients with thrombocytopenia
and to study whether the platelet-associated antibodies are associated with platelet Fcγ receptor
polymorphism, and
• to evaluate the measurement of reticulated platelets by using thiazole orange (TO) staining and flow
cytometry.
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MATERIALS AND METHODS
1. ETHICAL ASPECTS
Approval for these studies was obtained from the Ministry of Social Affairs and Health in Finland. The
ethical committee of the Finnish Red Cross Blood Transfusion Service accepted the plan of the study.
2. STUDY SUBJECTS
2.1. Patients
Consecutive blood samples that were sent to the Platelet Laboratory at the Finnish Red Cross Blood
Transfusion Service from patients with histories of thrombocytopenia for detection of platelet antibodies
were included in the studies if sufficient platelets for these additional investigations could be isolated (I-
III). A total of 438 samples were investigated (I-IV; Table 7). The diagnoses of the different groups of
patients are summarised in Table 8.
Table 7. Material and methods used in different studies.
Study I Study II Study III Study IV
Patients (n) 159 115+1* 113 50
Controls (n) 495 153 93 54
PIFT† PA-IgG PA-IgG PA-IgG PA-IgG
MAIPA** GP IIbIIIa+IbIX+IaIIa,
GP V
GP IIbIIIa+IbIX,
GP V
GP IIbIIIa+IbIX
FcγRIIA FcγRIIA
RP RP
* Of the total 882 thrombocytopenic patients screened for PA-IgG, 115 samples with strongly positive PA-IgG
(fluorescence intensity >400) were included. Additional patient with gold-induced thrombocytopenia was included as a
case report. Forty-three (of 115, 37%) were also included in Study III.
† detection of PA-IgG. ** detection of GP-specific PA-IgG.
FcγRIIA: Fcγ receptor type IIA genotyping; GP: glycoprotein; MAIPA: monoclonal antibody-specific immobilization of
platelet antigens; PA-IgG: platelet-associated IgG; PIFT: platelet immunofluorescence test;
RP: reticulated platelets detected by flow cytometry
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Study I. Samples from 159 patients (mean age 50 years, range 0-87 years; 87 male patients) were
collected during a 14-week period (November 1993-March 1994).
Study II. Samples from altogether 882 patients were collected during a 15-month period (July 1995-
October 1996). Of these 882 patients, only samples with strong positive PA-IgG (median fluorescence
intensity >400) were included, n=115 (mean age 50 years, range 7-87 years; 45 male patients). In
addition, one female patient with seronegative rheumatoid arthritis and gold-induced thrombocytopenia
was included in the study as a case report. First, the platelet count was found to be normal (218 x 109/l),
but seven months after the initiation of gold therapy with altogether 810 mg of sodium aurothiomalate,
purpura appeared on the lower extremities and mucosal bleeding started. The platelet count was 65 x
109/l with a nadir of 5 x 109/l 6 days later. Bone marrow examination and abdominal ultrasound scanning
were normal. Sodium aurothiomalate injections were discontinued and prednisone treatment was started,
60 mg daily with declining dosage.
Study III. Samples from 113 patients (mean age 47, range 4-84 years, 55 male patients) were collected
during an 11-month period (July 1995-May 1996; with an additional 10 months for Group II). Group I
comprised 36 (20 female) patients with strongly positive PA-IgG (median fluorescence intensity >400)
and strongly positive GP IIbIIIa and/or GP IbIX-specific PA-IgG (ratio >4.0). Group II consisted of 13
(8 female) patients with strongly positive PA-IgG and negative GP IIbIIIa or GP Ib-specific PA-IgG (ratio
< 1.5). Group III comprised 64 (30 female) patients with negative PA-IgG (fluorescence intensity < 280)
and no demonstrable GP IIbIIIa or Ib-specific PA-IgG (ratio <1.2).
Study IV. Samples from 72 women patients were sent for detection of platelet antibodies from two
hospitals (Department of Obstetrics and Gynecology, Helsinki University Hospital and Helsinki City
Maternity Hospital) during a 1-year period (August 1997-July 1998). The criteria for inclusion were that
samples were from women with either maternal (platelet count <130 x 109/l) or neonatal (platelet count
<150 x 109/l) thrombocytopenia. Twenty-two patients were excluded because of more complicated
medical histories. The remaining 50 patients were subclassified as follows: Group 1A (n=11) consisted
of thrombocytopenic pregnant women in the third trimester. Group 1B (n=9) consisted of
thrombocytopenic women after full-term pregnancy, samples obtained after delivery. Group 2 (n=30)
consisted of healthy mothers after full-term pregnancy with a thrombocytopenic newborn infant.
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Table 8. Diagnoses of patients in Studies I-IV
Study III†
Diagnosis * Study I Study II Group I Group II Group III Study IV
n 159 115+1** 36 13 64 50
ITP 52 28 9 6 23
Haematological neoplasia 16 7 4 1 8
Collagenosis 12 6 4 3
TP and anaemia 8 4 2
Infection 10
Chronic liver disease 9 5 1 1
Rheumatoid arthritis 7 6 1 2
gold-induced TP 1**
Neoplasia with TP 2 7 2
Drug-induced TP 4 6 1 1 1
Pancytopenia 3 3 3 2 4
Inflammatory bowel disease 2 4
Thrombotic TP 2 2
Renal disease 6
Pregnancy with TP 3 11
TP, after full-term pregnancy 9
no TP, newborn with TP 30
Thyroid disease 2
Miscellaneous TP 17 31 8 2 15
no TP 12 2 5
* Patients were compiled from routine samples sent to our laboratory for analysis of platelet antibodies. Diagnoses are
based on the clinical data supplied (I-III) or collected from the records (IV).
† Group I: strongly positive platelet-associated IgG (PA-IgG) and positive GP-specific PA-IgG; Group II: strongly
positive PA-IgG and no GP-specific PA-IgG; Group III: no PA-IgG or GP-specific PA-IgG.
** Of the total 882 thrombocytopenic patients screened for PA-IgG, samples with strongly positive PA-IgG were
included, n=115. Additional patient with gold-induced thrombocytopenia was included as a case report. Forty-three (of
115, 37%) were also included in Study III.
ITP: idiopathic thrombocytopenic purpura; TP: thrombocytopenia
2.2. Controls
Platelet samples from healthy blood donors were used as random controls.
Direct PIFT (I-IV). In each test series we examined a fresh platelet sample and a pooled sample from five
donors as negative controls, and a sensitised sample as a positive control. A total of 495 (I) and 153 (II,
III) control samples were investigated.
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Direct MAIPA (I-III). At least two negative controls and a sensitised positive control were examined in
parallel by direct MAIPA in each test series. In GP V-specific direct MAIPA, 18 negative controls and
a sample from a patient with strong positive GP V-specific PA-IgG were used as controls (II).
FcγRIIA genotyping (III). The distribution of the FcγRIIA polymorphism was determined in 93 (45
female) donors.
Reticulated platelets (IV). Samples from 54 donors (mean age 39 years) were investigated: 38 were male
(70 %; age range 24-66 years) and 16 female (range 27-51 years). At least one control sample was used
in each test series.
3. METHODS
3.1. Platelet preparation and storage
Blood samples from patients (27 ml of venous blood anticoagulated with 3 ml of liquid 5% Na2EDTA
in phosphate-buffered saline (PBS) in plastic tubes (Falcon; Becton Dickinson, Lincoln Park, New
Jersey) were sent overnight to our laboratory. Control samples consisted of 10 ml of blood. Platelets were
isolated by differential centrifugation, and the platelet suspension was washed three times with a solution
of PBS containing 0.2% bovine serum albumin (BSA). Platelets were fixed in a solution of 1%
paraformaldehyde in PBS for 5 min at room temperature (RT), and then washed twice. The platelet
concentration was determined with an electric cell counter (Medonic, Solna, Sweden). The final
concentration of the washed platelet suspension was adjusted to 500 x 109/l for direct PIFT and for
analysis of reticulated platelets. For direct MAIPA, the platelets were washed once more and suspended
in physiological NaCl to a final platelet concentration of 1000 x 109/l. The platelets were stored for no
longer than 2 weeks at +4 oC (I) or at -70 oC (II, III).
3.2. Detection of PA-IgG and GP-specific PA-IgG
Platelet-associated IgG (PA-IgG) and GP-specific PA-IgG were detected with the direct PIFT (I-IV)
and the direct monoclonal antibody-specific immobilisation of platelet antigens (MAIPA; I-III),
respectively.
3.2.1. Direct platelet immunofluorescence test (Direct PIFT)
PA-IgG was measured by direct PIFT (von dem Borne et al, 1978). Freshly prepared platelet suspension
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(500 x 109/l) containing a total of 50 x 106 platelets, was incubated with 100 µl of diluted fluoro-
isothiocyanate-conjugated rabbit anti-human IgG, specific for the Fc fragment (DAKO, F-123; Dakopatts
A/S, Copenhagen, Denmark). After incubation for 30 min at 37 oC on microtitre plates precoated with
BSA, the platelets were washed once with 1% BSA in Na-phosphate EDTA-buffer solution. The platelets
were then diluted in 1 ml of buffer for analysis with a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA, USA) equipped with a 15.2 mW air-cooled 488 nm argon-ion laser. Logarithmic
amplification was used on the FSC, side light scatter and fluorescence intensity (FL). Data of 2 000
ungated events were analysed with a software program (Lysys II, Becton Dickinson). In each test series,
an FSC versus side light scatter dot plot was used to draw a gate containing the majority of the platelet
population of the control sample. The median value of the FL was used to determine the value for PA-
IgG. In each test series we examined a fresh platelet sample from one healthy blood donor as a random
negative control (n=495; mean FL 221, median 217, SD 47, CI 217-225) during over a 4-year period (I),
and (n=153, mean FL 212, median 210, SD 39, CI 205-218, CV 18.4%) during a 15-month period (II).
The control values were normally distributed (Shapiro W test, P<0.0001). A pooled sample from five
healthy blood donors serving as a negative control (median 186, CV 5.9%), and a sensitised platelet
sample as a positive control (median 605, CV 1.4%) were also examined in each test series. Quality
control of the instrument was carried out in each test series using standard labelled (median 790, CV
1.0%) and unlabelled (median 315, CV 1.8%) fluorescent beads (CaliBRITE Beads, Becton Dickinson).
In Study I, an FL of 300 (mean + 2 SD) was taken as an arbitrary cut-off value above which sample was
positive. In Study II, a sample was considered positive when the median FL was >300 and strongly
positive when >400.
3.2.2. Direct monoclonal antibody-specific immobilisation of platelet antigens (Direct MAIPA)
The direct MAIPA (Kiefel et al, 1991) was modified. The following monoclonal antibodies were used:
AP1, specific against the GP Ibα (Okita et al, 1985; a generous gift from Dr R Montgomery, Milwaukee,
WI, USA); AP2, specific against the GP IIbIIIa complex (Pidard et al, 1983; a generous gift from Dr R
Montgomery, Milwaukee); Gi9, specific against the GP IaIIa purchased from Immunotech (Marseille,
France); SW16, specific against the GP V (Modderman et al, 1992; purchased from the Central
Laboratory of the Netherlands Red Cross, Amsterdam, Netherlands).
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Study I. The platelet suspension (1000 x 109/l) of 60 µl was washed once with 0.9% NaCl and
resuspended in PBS containing 2% BSA. Aliquots of 0.2 µg of each of the three monoclonal antibodies,
AP2, AP1 and Gi9, were applied simultaneously to the platelets and incubated for 30 min at 37 oC. For
separate measurements of GP Ib- and GP V-specific antibodies, 0.2 µg of monoclonal antibody AP1 or
SW16 was added to 25 µl or 40 µl, respectively, of the platelet suspension. After washing three times
with 0.9% NaCl, the platelets were solubilised in detergent (0.5% Triton X-100, 1.21 g/l Tris in isotonic
saline) and incubated for 30 min at +4 oC. The platelet lysates were centrifuged at 13 000 rpm for 15 min,
and 50 µl of the supernatant was transferred to tubes containing 200 µl Tris-buffered saline (TBS) in
which the samples were stored overnight at +4 oC. The wells of a microtitre plate (A/S Nunc, Roskilde,
Denmark) were coated with goat polyclonal anti-mouse IgG (Jackson Immunoresearch Inc., West Grove,
PA) diluted 1:500 with a coating buffer (0.015 M NaCO3, 0.035 M NaHCO3, pH 9.6, containing 0.02%
NaN3) in triplicate, washed six times with an automatic microtitre plate washer (MultiWash, Tri-
Continent Scientific, Grass Valley, CA), and blocked for 30 min at RT with TBS before addition of 70
µl of lysate to each well. After incubation for 90 min at +4 oC, the wells were washed six times, and 100
µl of peroxidase-conjugated goat anti-human IgG (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) diluted 1:2000 with TBS, was added. After incubation for 120 min at +4 oC, the wells were
washed six times with TBS. Substrate solution (1,2-phenylene-diamine, A/S DAKO, Denmark in citric-
phosphate buffer) was added, and after incubation for 30 min at RT, the absorbance was measured at 492
nm (Multiskan, Labsystem Ltd, Helsinki, Finland). The patient’s absorbance value was divided by the
mean negative control absorbance of each test series to obtain the relative absorbance. A sample was
considered positive when the relative absorbance was >1.5.
Study II and III. Frozen platelet suspensions (1000 x 109/l) of 25-µl aliquots were quickly thawed and
incubated with 0.2 µg of the monoclonal antibodies AP1 and AP2. For separate measurement of GP V-
specific PA-IgG, 0.2 µg of the monoclonal antibody SW16 was added to 80 µl of the platelet suspension.
Here, for the relative absorbance (patient’s absorbance value divided by mean negative control absorbance
of each test series), the term ‘ratio’ was used (same formula). A sample was considered positive when
the ratio was >1.5, and strongly positive when >4.0 (III) and >6.0 (II) . In the GP IIbIIIa- and/or GP IbIX-
specific direct MAIPA (II), negative and positive controls had interassay CVs for ratios 11% (median 1.1)
and 12.5% (median 22.0), respectively.
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Separately, 41 paired fresh and frozen samples were tested for GP IIbIIIa- and/or GP IbIX-specific PA-
IgG to check whether freezing affected the results. The ratios for the fresh and frozen samples (mean 1.6,
SD 1.7, range 0.9-11.7 and mean 1.6, SD 1.6, range 0.8-10.7, respectively) correlated well (Spearman
R=0.82, P<0.001). Samples from healthy blood donors (n=18) were used as negative controls in GP V-
specific direct MAIPA (median 1.0, range 0.9-1.0, CV 3.7%). The linearity of the method was
determined with a strong positive GP V-specific PA-IgG sample at successive platelet dilutions
(Spearman R=0.99, range of ratio 2.1-21.4).
3.3. Genotyping of the FcγRIIA
The genomic DNA of the leukocytes from buffy coats (extracted from EDTA-anticoagulated blood),
stored frozen at -20 oC, was isolated by a salting-out procedure (Miller et al, 1988). An FcγRIIA-gene-
specific fragment of approximately 1000 bp was first amplified according to Osborne et al (1994) with
modifications. PCR was performed by adding about 500 ng of the purified genomic DNA template to
50 µl of reaction mixture containing 25 pmol of each oligonucleotide primer, 5 µl of 10X Dynazyme
buffer, 2 U of DNA Polymerase (Dynazyme, Finnzymes, Espoo, Finland), and 5 µl of 2.5 mM
polymerisation mix (Pharmacia LKB Biotechnology, Upsala, Sweden). The steps in the PCR analysis
for the thermal cycler (DNA engine, MJ Research, Inc., Watertown, Massachusetts) were 3 min
denaturation at 96 oC, amplification for 30 cycles of 1 min at 96 oC, 1 min at 58 oC, and 1 min at 72 oC.
Then 5 µl of the product obtained by PCR was analysed by electrophoresis on 1.5% agarose gel. The
genomic FcγRIIA 494-G/A polymorphism does not lead to formation or loss of a restriction site.
Therefore, a nested PCR was performed using the FcγRIIA-specific product as a PCR template according
to de Haas et al (1995). The primers create a novel restriction site for BstUI (New England Biolabs,
Beverly, MA) in cases in which G was present at position 494. For the BstUI digestion, 8 µl of amplified
DNA product of 134 bp obtained from the second PCR was mixed with 4.5 µl of sterilised water, 1.5 µl
of the 10X buffer supplied with the restriction enzyme, and 1U of the restriction enzyme BstUI. After
incubation overnight, the fragments were analysed on a 3% agarose (NuSieve; FMC, Rockland, ME) gel
with a molecular weight standard (Fig 5). If there was a G at position 494, the digestion resulted in two
fragments of 115 bp and 19 bp. Samples repeatedly found to be of known genotypes were analysed in
each test series.
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Fig 5. BstUI restriction analysis of the 134-bp FcγRIIA-specific fragment containing the polymorphic nucleotide
494. A 1.0-kb FcγRIIA -specific fragment was amplified from genomic DNA, followed by nested PCR. With
mismatch the primers of the nested PCR created a BstUI restriction site in the R131 (494G) allele only.
Homozygous RR131 fragments were digested, resulting in bands 115 bp and 19 bp (not clearly visible; lane1). In
heterozygous HR131, two bands (134 bp and 115 bp) were visible (lane 2). Homozygous HH131 fragments were
not digested (lane 3).
3.4. Measurement and data analysis of platelets stained with TO (RP)
For the TO staining, the published procedures were modified (Ault et al, 1992; Bonan et al, 1993; Rinder
et al, 1993; Richards & Baglin, 1995). Samples were analysed within 48 hours. A paraformaldehyde-
fixed platelet suspension (500 x 109/l) of 10 µl was incubated with 90 µl of TO solution (RetiCount,
Becton Dickinson, San Jose, CA). After incubation for 60 min at RT in the dark, 400 µl of buffer was
added, and the platelets were analysed in a FACScan flow cytometer. For the first 21 series (29 patients
and 23 controls), data of 5 000 ungated events were collected and analysed with a CellquestTM Software
program (Becton Dickinson, San Jose, CA). In subsequent series, the number of events was increased
to 50 000. Logarithmic amplification of FSC, side light scatter and FL were used. FSC was plotted
against side light scatter, and this dot plot was used to draw a gate containing the majority of the platelets
(approximately 99%) in each test series. This gating was used to analyse the samples of that particular
series.
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Data analysis methods were based on two principles (Fig 6):
A. Patient median FL1. The values of FL and FSC for the patients’ samples and control samples were
plotted as histograms. Median values of FSC were obtained, and median FLs were also obtained for the
control and for the patients’ samples, Control median FL1 and Patient median FL1, respectively.
B. Relative FL1. To compare the results of the separate test series, a Relative FL1 was obtained for every
patient’s sample, using the formula: Relative FL1 = [(Patient median FL1 - Control median FL1): Control
median FL1] x 100.
C. % RP. A dot plot of FL vs. FSC was made for every patient sample and control sample. The dot plot
of the control sample was used in the analysis settings. A line was drawn at the edge of the platelet cluster
corresponding to the slope of the platelet population. This slope line was adjusted to segregate 94.0-
95.9% of the events below the line (TO-negative). This setting was used to analyse the patients’ samples
for that particular series.
Ribonuclease (RNAase) treatment. To demonstrate the specificity of the TO staining of platelet RNA,
random platelet samples were treated with RNAase before the staining (Ribonuclease A, 50-100 Kunitz
units/mg, Sigma Chemical CO, St. Louis, MO). RNAase (5 µl; 1 mg/100 ml) was used to treat 20 µl of
platelet suspension for 30 min at +37 oC. The TO positivity (median FL1) was diminished in all the
patients tested (n=16; mean decrease 8.0%, CI 5.7-10.3 %) and control samples (n=5; mean 4.7%, CI 0.7-
8.7%).
3.5. Statistical analysis
The mean, median, SD, range and 95% confidence intervals (CI) were calculated to provide estimates
(I-IV). Correlations were calculated with the Spearman rank order correlation (I, II, IV). Differences
between populations were calculated with the Mann-Whitney U test or the Student’s t test, taking P<0.05
as significant (I-IV). The Shapiro W test was used to evaluate a normal distribution (I). The coefficients
of variation (CV) were calculated for the methods (II). The distribution of FcγRIIA genotypes and allele
frequencies in patients and controls were compared by the exact 2 x k test (III). Fisher’s exact test was
used for comparing the age profiles between the groups of patients with different FcγRIIA genotypes (III).
In the statistical analysis, the software used comprised InStat (GraphPAD Software), StatXact 3 (CYTEL
Software Corporation) and Statistica for Windows (StatSoft inc.).
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Fig 6. Different ways of estimating the degree of fluorescence of thiazole orange (TO)-stained platelets in a control
sample and in a patient’s sample considered to be TO-positive. The fluorescence intensities were plotted as
histograms and median values were obtained for every control (A; Control median FL1 213) and patient samples
(B; Patient median FL1 304). The Relative FL1 for the patient’s sample was calculated: Relative FL1 = [(Patient
median FL1-Control median FL1): Control median FL1] x 100 (here, Relative FL1 42.7%). For the control sample,
the FSC versus FL1 scatter (% RP; C) was plotted. A sloping line segregating 95% of the events below the line was
set parallel to the platelet cluster, here leaving 4.3% of the events above the line. This setting was also used in the
analysis of the patient’s sample (D) in that particular test series. The % RP for the patient sample was 26.1%.
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RESULTS
1. SREENING FOR PA-IgG IN THROMBOCYTOPENIC PATIENTS (I-IV)
Study I. Direct PIFT for measuring PA-IgG on patient’s platelets was considered to be positive (an
arbitrary cut-off value of 300 for median fluorescence intensity) in 53% (84/159) of the patients (Fig 7).
Strongly positive PA-IgG (median fluorescence intensity >400) was found in 25 (16%) patients (Fig 8).
Fig 7. Results of the direct PIFT for platelet-associated IgG (PA-IgG) and the direct MAIPA for GP-specific
PA-IgG in Study I. * Samples were not studied for GP IbIX-specific PA-IgG.
Study II. Direct PIFT for measuring PA-IgG was positive (median fluorescence intensity >300) in 41%
(366/882) of the patients. Strongly positive PA-IgG (median fluorescence intensity >400) was found in
115 (13%) patients (Fig 8). One additional patient with gold-induced thrombocytopenia (presented as a
case report) had strongly positive PA-IgG (fluorescence intensity 503).
Study III. Group I (n=36) and Group II (n=13) consisted of samples from patients with strongly positive
PA-IgG (median fluorescence intensities >400). The samples in Group I were also positive for GP-
specific PA-IgG, whereas those in Group II had no GP-specific PA-IgG. PA-IgG was shown to be higher
in Group I than in Group II (mean fluorescence intensity 524, SD 112 vs. mean 433, SD 21 Mann-
Whitney U test, P=0.003), indicating that the antibody profiles of the two groups differed significantly
from each other.
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Fig 8. Comparison between the median fluorescence intensities for PA-IgG measured by the direct PIFT and the
ratios for glycoprotein (GP)-specific PA-IgG measured by the direct MAIPA in 140 patients with fluorescence
intensities >400. Combined results of Studies I and II.
Study IV. Altogether 50 patients were examined, and PA-IgG was positive (median fluorescence intensity
>300) in 4 of 11 pregnant women with thrombocytopenia (Group 1A), in 3 of 9 thrombocytopenic
women after full-term pregnancy (Group 1B) and in 3 of 30 healthy women with a thrombocytopenic
newborn infant (Group 2). PA-IgG was shown to be higher in Group 1A than in Group 2 (mean
fluorescence intensity 293, median 289, SD 57, CI 255-331 vs. mean 235, median 226, SD 54, CI 215-
255; Mann-Whitney U test, P=0.003).
2. GP-SPECIFIC PA-IgG (I-II)
Study I. Of the patients who were positive for PA-IgG, 51% (43/84) were also positive for GP IIbIIIa-
and/or GP IbIX- and/or GP IaIIa-specific PA-IgG (Fig 7). In addition, 2% of the patients (3/159) with no
PA-IgG were weakly positive for GP-specific PA-IgG (range of ratio 1.5-1.9), suggesting that the PIFT
was a sensitive method and suitable as a reference method. Of all the patients, 29% (46/159) were
positive for GP IIbIIIa- and/or GP IbIX- and/or GP IaIIa-specific PA-IgG (Fig 7).
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The correlation between the fluorescence intensities for PA-IgG and the relative absorbances for GP
IIbIIIa- and/or GP IbIX- and/or GP IaIIa-specific PA-IgG was significant (Spearman R=0.79, P<0.001;
Fig 8). The fluorescence intensities for PA-IgG in the patients who were positive for GP IIbIIIa- and/or
GP IbIX- and/or GP IaIIa-specific PA-IgG were higher than in those with no GP-specific PA-IgG (n=46,
mean 411, median 395, SD 81, CI 387-435 vs. n=113, mean 284, median 272, SD 59, CI 273-294; Mann-
Whitney U test P<0.001). Among the patients who were positive for GP IIbIIIa- and/or GP IbIX- and/or
GP IaIIa-specific PA-IgG, the fluorescence intensities for PA-IgG were higher in the female (n=18) than
in the male (n=28) patients (mean 451, median 452, SD 76, CI 413-489 vs. mean 386, median 365, SD
68, CI 357-414; Mann-Whitney U test, P=0.004).
Study II. GP IIbIIIa- and/or GP IbIX- specific PA-IgG were found in 20% (176/882) of the patients. GP
IIbIIIa- and/or GP IbIX-specific PA-IgG was positive in 83% (95/115) of the patients who were strongly
positive for PA-IgG. Of the 366 patients who were positive for PA-IgG, 206 (56%) were also positive
for GP IIbIIIa- and/or GP IbIX- and/or GP IaIIa-specific PA-IgG. In addition, 16 patients (2% of 882
patients) with no PA-IgG were weakly positive for GP-specific PA-IgG. In the study population of 882
patients, the correlation between the fluorescence intensities for PA-IgG and the ratios for GP IIbIIIa-
and/or GP IbIX- specific PA-IgG was significant (Spearman R=0.64, P<0.001), as expected from the
results of Study I.
Patients with the most strongly positive responses to both PA-IgG and GP-specific PA-IgG seemed to
have thrombocytopenia of suggested autoimmune origin (I, II; Table 9).
3. GP V-SPECIFIC PA-IgG (I-II)
Study I. Positive GP V-specific PA-IgG was demonstrated for 13 (10%) patients of the 125 whose
samples were studied (Fig 7). Of these 13 patients, 12 were positive for PA-IgG by direct PIFT, of whom
seven were strongly positive. Ten patients were also positive for GP IIbIIIa- and/or GP IbIX- and/or GP
IaIIa-specific PA-IgG (Table 9). GP V-specific PA-IgG was detectable even in the samples with no
demonstrable GP IbIX-specific PA-IgG (5 patients; Fig 7), suggesting a separate sole target role of GP
V. However, samples in which both GP V-specific and GP IbIX-specific PA-IgG were detected showed
a significant correlation between the relative absorbances (R=0.82).
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Table 9. Thrombocytopenic patients with strongly positive platelet-associated IgG (PA-IgG) and
positive glycoprotein V (GP V)-specific PA-IgG in Studies I and II.
Patient Study Sex Age Diagnosis PA-IgG*
GP IIbIIIa and/or
IbIX and/or IaIIa
PA-IgG†
GP V
PA-IgG†
1 II f 58 SS with gold therapy 646 4.9 21.8
2 I m 43 RA with gold therapy, TP 592 6.3 20.1
3 I f 69 Liver disease, TP 575 5.5 12.2
4 II m 20 ITP, AIHA 566 3.4 15.3
5 II f 69 RA with gold therapy, TP 565 2.9 22.4
6 I f 50 RA with gold therapy, TP 545 4.9 3.7
7 I m 69 Quinidine therapy 541 8.8 11.7
8 II f 31 ITP 528 3.5 7.8
9 II f 13 Anaemia, TP 519 4.4 4.8
10 II m 37 ITP 491 5.3 2.0
11 I m 60 ITP, AIHA 487 7.5 3.9
12 II f 44 Thrombosis, TP 463 3.5 1.9
13 II f 76 Quinidine-induced TP 462 1.3 7.7
14 II f 25 TP 457 2.6 2.7
15 II m 59 RA 454 2.0 2.0
16 II f 65 SLE 451 3.8 1.9
17 I f 28 Glomerulonephritis, TP 448 4.3 3.5
18 II f 31 Anaemia, TP 446 3.2 2.8
19 II m 19 ITP 442 3.2 12.4
20 II m 51 TP 424 2.3 14.0
21 II m 37 Liver disease, TP 422 1.5 1.5
22 I f 3 TP 415 1.2 1.8
case** II f 54 RA, gold-induced TP 503 2.5 18.6
* Median fluorescence intensities for PA-IgG >400 by PIFT were considered strongly positive.
† Ratios for GP specific PA-IgG >1.5 by MAIPA were considered positive. The samples were studied when fresh (I) or
after freezing (II). ** Additional patient included as a case report.
Patients with strongly positive PA-IgG by direct PIFT and positive GP V-specific PA-IgG by direct MAIPA were
included. AIHA: autoimmune haemolytic anaemia; ITP: idiopathic thrombocytopenic purpura; RA: rheumatoid arthritis;
SLE: systemic lupus erythematosus; SS: Sjögren`s syndrome; TP: thrombocytopenia
Study II. Positive GP V-specific PA-IgG was found in 15 (22%) of the study population’s 69 samples
(Table 9). In seven samples, the GP V-specific PA-IgG was considered strongly positive (ratio >6.0).
Thus, a positive GP V-specific PA-IgG partly explained (15/69, 22%) the strongly positive PA-IgG.
One patient with strongly positive PA-IgG and strongly positive GP V-specific PA-IgG had no GP
IIbIIIa- or GP IbIX-specific PA-IgG (Table 9, Patient 13). Strongly positive GP V-specific PA-IgG was
found in seven samples without strongly positive GP IIbIIIa- and/or GP IbIX-specific PA-IgG. Of the 46
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samples with strongly positive PA-IgG but without sufficient platelets (i.e. which could not be studied
for GP V-specific PA-IgG), 13 were strongly positive for GP IIbIIIa- and/or GP IbIX-specific PA-IgG.
The ratios for GP IIbIIIa- and/or IbIX-specific PA-IgG and those for GP V-specific PA-IgG were directly
correlated (Spearman R=0.53, P<0.001).
One additional patient with gold-induced thrombocytopenia had initially strongly positive GP V-specific
PA-IgG (ratio 18.6; presented as a case report, Table 9). Two additional samples obtained during
recovery from thrombocytopenia in the following 3 months showed that strongly positive GP V-specific
PA-IgG was still present but declining.
4. POLYMORPHISM OF THE PLATELET FCγRIIA H131R (III)
Among the 93 Finnish blood donors tested, the genotypes HH131, HR131 and RR131 were found in 25
(27%), 55 (59%) and 13 (14%), respectively, and thus the frequency of the H131 allele was 0.56 and that
of R131 was 0.44 (CI: 0.37-0.51). The distribution of the FcγRIIA alleles of Finnish blood donors did
not differ significantly from that of other Caucasians (Table 10).
Nor did the frequencies of H131R polymorphism of FcγRIIA differ significantly among the three sets of
patients grouped according to their PA-IgG profiles (altogether 113 patients). Furthermore, the groups
did not differ significantly from the controls (allelic frequencies in Table 11). However, a trend towards
a higher frequency of genotype RR131 of FcγRIIA in patients with no detectable PA-IgG (Group III) was
observed (Exact 2 x k test, P=0.10). When the fluorescence intensities for PA-IgG in the patients were
grouped according to the FcγRIIA genotypes, those with the genotype HH131 showed a tendency to have
higher intensities than those with RR131 (Mann-Whitney U test, P=0.082). The genotype RR131 was
found in 26 of 113 (23%) patients compared with 13 of 93 (14%) controls. Interestingly, the female
patients with the genotype RR131 (n=15) were younger than those with the genotype HH131 (Mann-
Whitney U test, P=0.065). Among the female patients, there were significantly more under 40 years old
in the RR131 group than in the HH131 group (Fisher’s exact test, P=0.006). Within the RR131 group,
the female patients were remarkably younger than the male patients (median age 29 vs. 61 years; Mann-
Whitney U test, P=0.002).
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Table 10. Frequencies of the Fcγ receptor type IIA (FcγRIIA) alleles in different populations.
Population H131 R131 CI for R131 n Reference
Finnish 0.56 0.44 0.37-0.51 93 (III)
Caucasian 0.46-0.50 (1947)
Caucasian 0.47 0.53 264 Denomme et al, 1997
Caucasian 0.45 0.55 259 Botto et al, 1996
Caucasian 0.54 0.46 256 Carlsson et al, 1998
Caucasian 0.56 0.44 218 Bachelot-Loza et al, 1998
Caucasian 0.51 0.49 187 Manger et al, 1998
Caucasian 0.59 0.41 167 Bachelot et al, 1995
Dutch 0.53 0.47 123 Reilly et al, 1994
Caucasian 0.47 0.53 102 Arepally et al, 1997
European 0.58 0.42 69 Duits et al, 1995
British 0.47 0.53 66 Smyth et al, 1997
Caucasian 0.53 0.47 61 Williams et al, 1998
Greek 0.62 0.38 52 Smyth et al, 1997
American 0.55 0.45 47 Sanders et al, 1994
Caucasian 0.50 0.50 41 Atsumi et al, 1998
Caucasian 0.50 0.50 35 Osborne et al, 1994
Asian 0.22-0.36 (206)
Japanese 0.78 0.22 105 Kobayashi et al, 1997
Chinese 0.69 0.31 49 Botto et al, 1996
Japanese 0.77 0.23 18 Osborne et al, 1994
Chinese 0.72 0.28 18 Osborne et al, 1994
Indian 0.39 0.61 16 Osborne et al, 1994
African 0.46-0.58 (277)
African-American 0.52 0.48 100 Salmon et al, 1996
Afro-Caribbean 0.45 0.55 77 Botto et al, 1996
African-American 0.44 0.56 50 Norris et al, 1996
African-American 0.44 0.56 50 Sanders et al, 1994
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Table 11. Fcγ receptor type IIA (FcγRIIA) allelic frequencies in patients and in controls.
n H131 (n) R131 (n) CI for R131
Group I* 36 0.58 (42) 0.42 (30) 0.31-0.53
Group II† 13 0.42 (11) 0.58 (15) 0.39-0.77
Group III** 64 0.48 (61) 0.52 (67) 0.44-0.60
Controls 93 0.56 (105) 0.44 (81) 0.37-0.51
* Strongly positive platelet-associated IgG (PA-IgG; fluorescence intensity >400) and positive GP-specific PA-IgG
(relative absorbance >4.0).
† Strongly positive PA-IgG and no GP-specific PA-IgG (relative absorbance <1.5).
** No PA-IgG (fluorescence intensity <280) or GP-specific PA-IgG (relative absorbance <1.2).
5. RETICULATED PLATELETS (IV)
In 50 patients, fluorescence for TO positivity was estimated in three different ways: Patient median FL1,
Relative FL1 and % RP (Fig 9; Table 12). The Patient median FL1 of pregnant women with
thrombocytopenia (Group 1A) was significantly higher than that of healthy women with a
thrombocytopenic newborn infant (Group 2; mean 306, SD 40, CI 279-332 vs. mean 266, SD 30, CI 255-
277; Mann-Whitney U test P=0.004; Table 12, Fig 10), suggesting that RP reflect increased platelet
production and features of pathological thrombocytopenic conditions. The patients in Group 1A had
stronger Patient median FL1 than the female controls (Mann-Whitney U test, P<0.001), whereas there
was no such difference between the patients of Group 1B (thrombocytopenic women after full-term
pregnancy) or Group 2 and the female controls. In Group 1A, a significant correlation was observed
between the Patient median FL1 and Patient median FSC (Spearman R= 0.62, P=0.043) but in the other
groups we found no correlation.
The Patient median FL1 was higher in the 50 detected patients than in the female controls (mean 277,
SD 36, CI 266-287 vs. mean 249, SD 34, CI 231-268; Mann-Whitney U test, P=0.015). The correlation
between the Patient median FL1 and Patient median FSC was significant (Spearman R=0.33; P=0.021),
whereas no correlation was observed between the Control median FL1 and Control median FSC
(Spearman R=0.21, P>0.05).
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Fig 9. Comparison of different ways of estimating the degree of fluorescence (FL) of platelets stained with thiazole
orange (TO) in 50 patients. A. The fluorescence intensities were plotted as histograms, and a median value was
obtained for every patient’s sample (Patient median FL1). The Relative FL1 for the patient’s sample was calculated:
Relative FL1 = [(Patient median FL1-Control median FL1): Control median FL1] x 100 in each test series. B. The
forward light scatter versus the FL1 plot of a control sample was used to obtain % RP (reticulated platelets) for a
patient’s sample.
Pregnant women with thrombocytopenia (Group 1A) also had higher levels of PA-IgG than healthy
women with a thrombocytopenic newborn (Group 2; Mann-Whitney U test, P=0.003; Table 12).
Fluorescence intensities for PA-IgG and Patient median FL1 for RP correlated significantly (Spearman
R=0.30, P=0.032).
Fig 10. Comparison of the thiazole orange (TO) positivity (Patient median FL1) in two groups of patients: 11
pregnant women with thrombocytopenia (Group 1A) and 30 healthy mothers with a thrombocytopenic newborn
infant (Group 2). The difference was significant (Mann-Whitney U test, P=0.004).
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Table 12. Different ways of estimating the degree of fluorescence of thiazole orange (TO) stained
platelets and platelet-associated IgG (PA-IgG) in patients and controls.
Thrombocytopenic women Healthy women
during pregnancy after delivery newborn with TP
Group 1A Group 1B Group 2 Controls
n 11 9 30 54
median FL1 mean 306* 278 266 267
median 304 292 262 271
SD 40 35 30 37
CI 279;332 251;304 255;277 257;277
range 236;370 215;325 207;324 192;350
Relative FL1 mean 12† 3.8 -1.1
(%) median 2 7 -4.5
SD 20 8.5 11
CI -1.4;25 -2.8;10 -5.1;2.9
range -9;45 -11;14 -19;22
% RP mean 7.1 3.9 6.8
median 4.3 4.4 5.3
SD 8.6 1.1 5.1
CI 1.4;12.9 3.1;4.8 4.9;8.8
range 0.4;27 1.6;5.4 0.6;19.6
FSC mean 447** 421†† 388 383
median 441 422 391 388
SD 47 37 21 25
CI 416;479 392;449 380;396 376;390
range 395;537 368;486 336;421 308;433
PA-IgG mean 293*** 257 235
median 289 229 226
SD 57 65 54
CI 255;331 207;307 215;255
range 227;400 187;362 165;405
* Group 1A vs. Group 2: P=0.004 and Group 1A vs. Controls: P=0.006 by the Mann-Whitney U test.
† Group 1A vs. Group 2: P=0.037.
** Group 1A vs. Group 2: P<0.001; Group 1A vs. Controls P<0.001; †† Group 1B vs. Group 2: P=0.01; Group 1B vs.
Controls: P=0.005. *** vs. Group 2: P=0.003.
Median FL1: Median fluorescence intensity (FL) of TO stained platelets obtained with FL histogram;
Relative FL1: [(Patient median FL1-Control median FL1) : Control median FL1] x 100;
% RP: TO-positive platelets determined from a forward light scatter (FSC) vs. FL plot using a segregating line (4-6%) in a
control sample; FSC: Median FSC of TO stained platelets with FSC histogram; PA-IgG: detected by PIFT, >300 was
considered positive; TP: thrombocytopenia.
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DISCUSSION
1. DETECTION OF PLATELET AUTOANTIBODIES
The direct platelet immunofluorescence test (PIFT) allows sensitive, reproducible and reliable
determination of platelet-specific autoantibodies on the platelet surface (von dem Borne et al, 1978 &
1986b; Ault, 1988). Numerous assays have been used for the detection of platelet antibodies in
thrombocytopenic patients, but improvement of the specificity and deeper understanding of the assays
and of the disease itself will probably enhance agreement about the applications and usefulness of the
new methods. Of randomly chosen patients with heterogeneous histories of thrombocytopenia collected
at separate periods of time, half the patients were positive for PA-IgG in the direct PIFT (I, II). Only 2%
of the patients in the two studies were demonstrated to have GP-specific PA-IgG, while the reference
method gave negative results. This may partly be explained by the low cut-off limit for positivity in
MAIPA. In comparison, Brighton et al (1996), using MAIPA, found GP-specific PA-IgG in 10% (8/81)
of patients with initially diagnosed immune thrombocytopenia and a negative result obtained with a
screening method (ELISA). Accordingly, the PIFT for measuring PA-IgG may well be used as a sensitive
reference method for screening PA-IgG when detecting platelet autoantibodies in patients with
thrombocytopenia due to different causes. Heterogeneous patient groups may be categorised according
to the PIFT result. Thus, PA-IgG serves as one device for defining the various forms of
thrombocytopenia.
Platelet GP IIbIIIa and GP IbIX appear to be important target autoantigens. GP IIbIIIa-, GP IbIX- or GP
IaIIa-specific autoantibodies were found in almost half the patients in whom the direct PIFT for PA-IgG
was positive. A positive direct PIFT with no detectable GP-specific PA-IgG may be caused by PA-IgG
against other antigens and also by non-specific antibodies on the platelet surface or immunocomplexes
bound by the platelet Fc receptor. With MAIPA, GP-specific PA-IgG was demonstrated in half the
patients with positive PA-IgG. Altogether, 20 to 30% of the patients with histories of thrombocytopenia
were demonstrated to have GP-specific PA-IgG. Using MAIPA, Brighton et al (1996) found GP-specific
PA-IgG in 49% (40/81) of patients with initially diagnosed immune thrombocytopenia and in 22%
(11/51) of patients with non-immune thrombocytopenia, whereas Warner et al (1999), with MAIPA,
found GP-specific PA-IgG in 39% (19/49) of patients with ITP and in 9% (3/32) of patients with initially
diagnosed non-immune thrombocytopenia. The modification of MAIPA (Berchtold et al, 1997) with
frozen platelet samples and monoclonal antibodies immobilising GP IIbIIIa and GP IbIX was found by
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us to be suitable for the detection of GP-specific PA-IgG. The possibility that monoclonal antibody is
directed against an epitope close to the specific target of the autoantibody could be ruled out by using
different monoclonal antibodies against a single target protein but against different antigenic epitopes.
Since GP-specific PA-IgG has also been detected in patients with various forms of disease-related
thrombocytopenia (Berchtold et al, 1989c; Kurata et al, 1993; Pereira et al, 1995; Warner et al, 1999),
GP-specific methods allow further subclassification and categorisation of autoimmune thrombocytopenic
patients. A more thorough understanding of the significance of GP-specific PA-IgG is necessary.
Comparison of the PIFT with the direct MAIPA for the detection of PA-IgG showed that high
fluorescence intensities for PA-IgG were associated with high ratios for GP-specific PA-IgG.
Furthermore, it appeared that, in both studies, the thrombocytopenia in patients with strongly positive
responses to both PA-IgG and GP-specific PA-IgG seemed possibly to be of autoimmune origin (Table
9). However, not all the positive PA-IgG could be attributed to GP IIbIIIa-, GP IbIX-, GP IaIIa- or GP
V-specific antibodies, since almost half the patients with histories of thrombocytopenia remained
negative in GP-specific MAIPA when the screening test was positive. Until the mechanisms of
autoimmune thrombocytopenia have been fully clarified, it is also important to further characterise the
specific PA-IgG in the different subpopulations of thrombocytopenic patients with increased peripheral
platelet destruction due to different causes, and to further categorise the groups of patients according to
their antibody profiles in addition to their clinical features. This approach should be widely evaluated and
considered.
Little has been known about GP V-specific autoantibodies. In drug-induced thrombocytopenia,
especially, GP V-specific PA-IgG may be present more frequently than has previously been suspected.
GP V has rarely been demonstrated to be a target for platelet antibodies; GP V-specific circulating
antibodies have been reported in two studies and a total of nine patients (Stricker & Shuman, 1986;
Mayer & Beardsley, 1996). There have been no previous reports on the GP V specificity of PA-IgG.
When investigating GP specificity, the GP V-specific monoclonal antibody in a combination of different
monoclonal antibodies should also be included. But with additional monoclonal antibodies one might
find even more PA-IgG directed against other targets. It is to be hoped that definition of the
characteristics of the platelet autoantibodies involved in autoimmune thrombocytopenia in terms of
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glycoprotein target antigens and autoepitopes will help to explain the natural course and mechanism of
platelet autoimmunity.
Circulating drug-dependent antibodies in the sera of patients with quinidine- or quinine-induced
thrombocytopenia have mostly been reported to react with GP IIbIIIa or GP IbIX (Kunicki et al, 1978;
van Leeuwen et al, 1982; Nieminen & Kekomäki, 1992; Burgess et al, 1998). Stricker & Shuman (1986)
reported circulating GP V-specific quinidine-dependent antibodies in six patients with quinidine-induced
thrombocytopenia. In the present study, one patient with quinidine-induced thrombocytopenia had no
detectable GP IIbIIIa- or GP IbIX-specific PA-IgG, but strongly positive GP V-specific PA-IgG.
In gold-induced thrombocytopenia, patients with rheumatoid arthritis have been demonstrated to be
strongly positive for PA-IgG (von dem Borne et al, 1986a; Adachi et al, 1987). However, GP-specific
PA-IgG has not been reported. Here, the three patients with the strongest positivity for GP V-specific PA-
IgG were on gold therapy and the additional case presented had definite gold-induced thrombocytopenia
(Table 9). To the best of our knowledge, this is a new finding. The GP specificity of PA-IgG in gold-
induced thrombocytopenia and in other forms of thrombocytopenia, especially drug-induced
thrombocytopenia with a larger number of patients, calls for further investigation.
The material studied consisted of patient groups with heterogeneous histories of thrombocytopenia and
also with other disorders. Characterisation of patients into well-defined clinically homogenous subgroups
of autoimmune thrombocytopenia, especially in laboratory-based studies, seems difficult. A multicentre
study, in tight collaboration with the laboratory facilities, would be needed to obtain homogenous, well-
characterised groups of patients with exact criteria.
2. GENETIC POLYMORPHISM OF PLATELET FCγRIIA IN THROMBOCYTOPENIA
The polymorphism of FcγRIIA may have an effect on the pathogenesis of immune thrombocytopenia.
In the groups of thrombocytopenic patients with different PA-IgG profiles, the distributions of FcγRIIA
allele frequencies did not differ significantly from each other or from those of the controls. However,
there was a tendency for RR131 clustering in patients with no detectable PA-IgG and also tendency for
PA-IgG to be more abundant in patients with HH131 than in those with RR131. It is agreed that the
H131R polymorphism of FcγRIIA affects the ligand binding properties of the receptor for the different
IgG subclasses. Since the genetic polymorphism at residue 131 affects the functional properties of
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FcγRIIA, Fcγ receptors may be responsible for the susceptibility to or modification of the disease. Several
studies have aimed at clarifying the distribution of FcγRIIA allele frequencies in different groups of
patients (Lehrnbecher et al, 1999). In light of the present studies, the evidence that disease susceptibility
varies with FcγRIIA polymorphism remains weak (Table 5). Further studies of FcγRIIA alleles and
probably other FcγR polymorphisms in specifically defined groups of thrombocytopenic patients would
elucidate this question.
In patients with histories of thrombocytopenia and with heterogeneous backgrounds, the clustering of
platelet FcγRIIA genotypes in the different groups according to age and gender is a new finding. Study
III showed that patients with positive PA-IgG and no detectable GP-specific PA-IgG showed a tendency
to have the genotype RR131. In the RR131 group, there were also more female patients under 40 years
of age than in the HH131 group, suggesting different mechanisms of thrombocytopenia. Furthermore in
the RR131 group, the male patients were older than the female patients. It is also known that among
adults, ITP is more frequent in young women, 70% of female patients being under 40 years of age
(George et al, 1994). Patients expressing H131 may have a different role for FcγRIIA in the clearance of
PA-IgG, while individuals with R131 may have a different mechanism for developing autoimmune
thrombocytopenia. Recently, patients with ITP were shown to have a tendency towards the RR131
genotype (Williams et al, 1998; Table 5).
Phagocytosis may be modulated by several mechanisms, which may include as yet unknown factors that
influence the presentation of autoimmune thrombocytopenia. Platelet antibodies may trigger platelet
activation by FcγRs and thus mediate more efficient clearance of platelets from the circulation. That
platelets from females when stimulated by heat-aggregated IgG, released significantly more serotonin
than platelets from males (Moore et al, 1981), has been suggested to imply either increased amounts of
Fcγ receptors on platelets or more sensitivity to FcγR-induced platelet stimulation. Expression of FcγRs
also varies on phagocytoses. Thus, the distribution of FcγRIIA allele frequencies should be studied not
only in different immune-mediated disease conditions with well-defined characteristics, but also in
heterogeneous groups of thrombocytopenic patients with known immunological properties. It seems
likely that no single solution will be found, but rather the emphasis should be on the probable modifying
effects of FcγRIIA and other FcγR polymorphisms.
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3. MEASUREMENT OF RETICULATED PLATELETS IN THROMBOCYTOPENIA
The degree of fluorescence of thiazole orange (TO) stained platelets was analysed with methods based
on two different principles. The results obtained with methods based on the intensity of the fluorescence
(Patient median FL1) and the plot of FL versus FSC (% RP) showed no correlation, whereas those based
on the relative intensity of the fluorescence (Relative FL1) and the plot of FL versus FSC (% RP) were
correlated. An intra-assay control, a reference sample from a healthy blood donor, was applied to reduce
the variation between the different test series. This same intra-assay control had a modifying effect on
the results obtained with both Relative FL1 and % RP. This modifying effect may also have contributed
to the positive correlation between Relative FL1 and % RP. In the measurements of reticulated platelets,
it seems worthwhile to use a combination of different types of data analysis.
The proportion of reticulated platelets in normal adult controls has been shown to vary greatly, between
1% and 20% (Kienast & Schmitz, 1990; Bonan et al, 1993; Rinder et al, 1993; Richards & Baglin, 1995;
Watanabe et al, 1995; Chavda et al, 1996), including inter-individual and inter-assay variation as well
as the variation between the results obtained in different laboratories. Here, when the method based on
plotted FL and FSC (% RP) was used, the level of TO positivity in normal samples was found to be
between 4 and 6%. We did not aim at defining the exact percentages of RP. However, the range of
median fluorescence intensity values (median FL1) for blood donor samples was rather wide, partly
because it displayed the inter-assay variation and partly because it reflected the inter-individual variation.
Of the normal samples, the male controls were demonstrated to have higher fluorescence intensities for
TO positivity than the female controls. Bonan et al (1993) also demonstrated a significant difference in
the percentages of RP between normal males and females, the level being higher among the women. Such
a sex-related difference has not been confirmed. From previous reports, a relation is known to exist
between sex hormones and erythrocyte levels (Tarallo et al, 1994), but such a correlation has never been
demonstrated for platelet levels, although oestrogen receptors have been identified in megakaryocytes
(Tarantino et al, 1994). Thus, in the measurements of RP, careful selection of controls is important.
The binding of TO may be partly non-specific on accounting of the labelling of other platelet contents,
such as dense granules (Robinson et al, 1998). The non-specific staining may be prevented by
degranulating the platelets prior to the measurements. Like other colleagues (Ault et al, 1992; Dale et al,
1995; Richards et Baglin, 1995; Chavda et al, 1996; Joseph et al, 1996), we used RNAase to demonstrate
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that the TO staining is RNA specific. The TO positivity was diminished in both patients and controls.
Yet, there are many different ways in which different laboratories use control samples, data analysis and
interpretation of results. As controls, either lyophilised platelets, erythrocyte fluorescence, unstained
samples, control cut-off values or RNAase treatment have been used (Ault et al, 1992; Bonan et al, 1993;
Rinder et al, 1993; Romp et al, 1994; Richards & Baglin 1995; Saxon et al, 1998). Here, RNAase was
not applied in every test series, rather an internal control sample was used. Standardisation of the
procedures used in the analysis and investigations of RP and agreement in terms of sample preparation,
labelling procedures, using of control samples, data analysis and interpretation of results would help to
compare and combine the results obtained in different laboratories.
We were able to demonstrate a significant difference in TO positivity (Patient median FL1, Relative FL1)
between pregnant thrombocytopenic women in the third trimester and healthy mothers with
thrombocytopenic newborn infants, suggesting that the TO positivity could represent a real marker of an
increased proportion of RP. The percentages of RP have been demonstrated to be significantly lower in
pregnant women in the second trimester than in non-pregnant women (Rinder et al, 1994). In the first or
third trimesters no difference could be seen between pregnant and non-pregnant women, in spite of a
significant fall in the platelet count (Rinder et al, 1994). The fall in platelet count has been postulated to
be due either to dilutional aetiology of thrombocytopenia or to down-regulation of thrombopoiesis in
pregnancy. Significantly higher percentages of RP in four women with pre-eclampsia at 26 weeks, before
the onset of any clinical signs, was suggested to represent a predictive value of RP in pregnant women
at risk of hypertension and pre-eclampsia. This, together with our results, suggests that the measurement
of RP may be clinically warranted.
69
SUMMARY AND CONCLUSIONS
Autoimmune thrombocytopenia is an immune-mediated bleeding disorder. Direct immunological
methods for the detection of platelet antibodies have improved the specific measurements of platelet-
associated antibodies (PA-IgG). Although the findings of PA-IgG and also glycoprotein (GP)-specific
PA-IgG methods give additional knowledge of the disorder, understanding of the immunopathological
mechanisms and the presence of platelet antibodies in different conditions is still incomplete.
The aims of this study were to investigate the presence of PA-IgG and also GP-specific PA-IgG in
patients with thrombocytopenia. The possible target role of GP V was investigated separately (I, II).
Further, we aimed to elucidate the distribution of the platelet Fcγ receptor (FcγR) polymorphism in
thrombocytopenic patients with different PA-IgG profiles, i.e. the possible association between FcγRIIA
polymorphism H131R and PA-IgG (III). We also evaluated the measurement of reticulated platelets (RP),
presumed markers of thrombopoiesis, by using thiazole orange staining and flow cytometry (IV). Our
material comprised patients with heterogeneous histories of thrombocytopenia and also with other
disorders. Most of our patients could be divided into groups of, for example, ITP, drug-induced
thrombocytopenia, pregnancy-associated thrombocytopenia and disease-related thrombocytopenia,
although a large proportion of the patients could not be placed in any of these categories (I-III). Study IV
comprised a total of 50 samples from pregnant women with thrombocytopenia, thrombocytopenic women
after full-term pregnancy and healthy women with a thrombocytopenic newborn infant.
The results of the PA-IgG screening test, i.e. the direct PIFT, and direct MAIPA, for detection of GP-
specific PA-IgG, could be used to subclassify the patients further. A total of 159 and also of 882 patients
with heterogeneous histories of thrombocytopenia were screened for PA-IgG, and half the patients were
found to be positive for PA-IgG (I, II). Furthermore, GP IIbIIIa- and/or IbIX- and/or IaIIa-specific PA-IgG
was present in approximately half the patients with positive PA-IgG. The patients with strongly positive
PA-IgG, detected both with PIFT and with MAIPA, seemed to be clinically more homogeneous and to
have thrombocytopenia with autoimmune features. Thus, the importance of GP IIbIIIa and GP IbIX as
target antigens of PA-IgG was confirmed. Interestingly, in further studies, GP V was found to be an
important target antigen. One patient with quinidine-induced thrombocytopenia had no detectable GP
IIbIIIa- or GP IbIX-specific PA-IgG, but was strongly positive for GP V-specific PA-IgG. GP V-specific
PA-IgG was found in five patients with thrombocytopenia due to gold therapy. These are new findings.
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We hoped that categorisation of patients with heterogeneous forms of thrombocytopenia according to
FcγRIIA genotypes would elucidate the multifactorial mechanisms of thrombocytopenia. The clustering
of FcγRIIA genotypes in the different groups of patients, a total of 113 patients, according to age and
gender was a new finding. The distribution of the platelet FcγRIIA polymorphism was also determined
in 93 Finnish blood donors; the allele distribution did not differ significantly from that of other
Caucasians. The laboratory methods used for the genotyping of platelet FcγRIIA polymorphism and for
the detection of platelet antibodies may be considered reliable and reproducible. However, the
significance of the polymorphism in the disease susceptibility still remains unsolved. Prospective studies
of clinically selected groups of patients should help to clarify whether there is any connection between
FcγRIIA polymorphism and the immunological mechanisms, especially in ITP.
In the measurements of reticulated platelets (a total of 50 patients), significant differences were observed
between pregnant thrombocytopenic women and healthy women in the fluorescence of thiazole orange-
stained platelets. Furthermore, a significant difference was also noticed in PA-IgG profiles; pregnant
thrombocytopenic women had higher levels of PA-IgG than healthy women. Patients with positive PA-
IgG also tended to have high fluorescence intensities for RP. There is as yet no standardisation of the
procedures used in the analysis of RP, but our present study confirms that measurement of RP provides
an additional non-invasive means of evaluating the pathogenetic mechanisms of thrombocytopenia.
Internationally agreed consensus about the laboratory methodology would accelerate research in this
field.
Subclassification of patients into different categories according to laboratory findings seems worth while
as long as autoimmune thrombocytopenia remains a group of heterogeneous disorders. A large, perhaps
multinational study, would be needed to collect groups of thrombocytopenic patients with clinical
characteristics sufficiently homogeneous for further subclassification to establish positive diagnostic
criteria.
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